Sesquiterpene Synthase Gene and Protein by Chappell, Joseph & Greenhagen, Bryan T.
University of Kentucky
UKnowledge
Pharmaceutical Sciences Faculty Patents Pharmaceutical Sciences
1-3-2017
Sesquiterpene Synthase Gene and Protein
Joseph Chappell
University of Kentucky, chappell@uky.edu
Bryan T. Greenhagen
University of Kentucky, btgree0@uky.edu
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/ps_patents
Part of the Pharmacy and Pharmaceutical Sciences Commons
This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been accepted for inclusion in
Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Recommended Citation
Chappell, Joseph and Greenhagen, Bryan T., "Sesquiterpene Synthase Gene and Protein" (2017). Pharmaceutical Sciences Faculty
Patents. 165.
https://uknowledge.uky.edu/ps_patents/165
c12) United States Patent 
Chappell et al. 
(54) SESQUITERPENE SYNTHASE GENE AND 
PROTEIN 
(71) Applicant: University of Kentucky Research 
Foundation, Lexington, KY (US) 
(72) Inventors: Joseph Chappell, Lexington, KY (US); 
Bryan Greenhagen, Belmont, MA (US) 
(73) Assignee: University of Kentucky Research 
Foundation, Lexington, KY (US) 
( *) Notice: Subject to any disclaimer, the term of this 
patent is extended or adjusted under 35 
U.S.C. 154(b) by 23 days. 
This patent is subject to a terminal dis-
claimer. 
(21) Appl. No.: 14/121,245 
(22) Filed: Aug. 13, 2014 
(65) 
(63) 
(60) 
(51) 
(52) 
(58) 
(56) 
Prior Publication Data 
US 2014/0356926 Al Dec. 4, 2014 
Related U.S. Application Data 
Continuation of application No. 13/385,794, filed on 
Mar. 6, 2012, now Pat. No. 8,835,131, which is a 
continuation of application No. 12/259,497, filed on 
Oct. 28, 2008, now Pat. No. 8,192,950, which is a 
continuation of application No. 10/899,356, filed on 
Jul. 26, 2004, now Pat. No. 7,442,785. 
Provisional application No. 60/489,514, filed on Jul. 
24, 2003. 
Int. Cl. 
C12P 5100 
C12N 9188 
U.S. Cl. 
(2006.01) 
(2006.01) 
CPC ................. C12P 51007 (2013.01); C12N 9188 
(2013.01); C12Y 402103073 (2013.01); Cl2Y 
402/03047 (2013.01) 
Field of Classification Search 
CPC ........................................... C12N 15/00-15/82 
See application file for complete search history. 
References Cited 
U.S. PATENT DOCUMENTS 
4,693,905 A 9/1987 Japiskc et a!. ................ 426/599 
4,973,485 A 1111990 Rich ............................. 426/534 
5,260,086 A 1111993 Downton et a!. ............. 426/599 
5,589,619 A 12/1996 Chappell et a!. ............. 800/205 
5,824,774 A 10/1998 Chappell ....................... 530/350 
5,847,226 A 12/1998 Muller eta!. ................. 568/346 
5,981,843 A 1111999 Chappell et a!. ............. 800/301 
6,072,045 A 6/2000 Chappell ...................... 536/23.1 
6,468,772 B1 10/2002 Chappell et a!. ............. 435/183 
6,495,193 B2 12/2002 Hiramoto et a!. ............ 426/651 
6,495,354 B2 12/2002 Chappell et a!. ............. 435/183 
6,531,303 B1 3/2003 Millis eta!. .................. 435/155 
6,559,297 B2 5/2003 Chappell et a!. ............ 536/23.1 
6,569,656 B2 5/2003 Chappell et a!. ............. 435/183 
6,645,762 B2 1112003 Chappell et a!. ............. 435/325 
111111 1111111111111111111111111111111111111111111111111111111111111 
US009534237B2 
(10) Patent No.: US 9,534,237 B2 
(45) Date of Patent: *Jan. 3, 2017 
6,689,593 B2 2/2004 Millis et al. .................. 435/155 
6,890,752 B2 5/2005 Chappell et a!. ............. 435/325 
7,186,891 B1 3/2007 Chappell ....................... 800/298 
7,273,735 B2 * 9/2007 Schalk . C12N 9/88 
435/155 
7,405,057 B2 7/2008 Chappell ...................... 435/69.1 
7,442,785 B2 10/2008 Chappell ...................... 536/23.6 
7,622,614 B2 1112009 Julien ........................... 568/327 
7,790,426 B2 9/2010 Schalk .......................... 435/167 
8,106,260 B2 112012 Chappell ....................... 800/298 
8,192,950 B2 * 6/2012 Chappell. C12N 9/88 
435/41 
8,236,512 B1 8/2012 Zhao eta!. .................... 435/7.6 
8,263,362 B2 9/2012 Chappell ...................... 435/69.1 
8,354,504 B2 112013 Chappell ....................... 530/379 
8,445,231 B2 5/2013 Chappell ...................... 435/69.1 
8,722,363 B2 5/2014 Chappell ...................... 435/69.1 
8,741,651 B2 6/2014 Chappell . ...................... 435/468 
8,835,131 B2 * 9/2014 Chappell. C12N 9/88 
435/252.3 
2003/0166255 A1 9/2003 Chappell . ................... 435/252.3 
2003/0185956 A1 10/2003 Gradley ........................ 426/534 
2003/0203090 A1 10/2003 Kotachi et a!. ............... 426/489 
2004/0078840 A1 4/2004 Chappell ....................... 800/278 
2005/0210549 A1 9/2005 Schalk .......................... 800/287 
2006/0218661 A1 9/2006 Chappell ....................... 800/278 
(Continued) 
FOREIGN PATENT DOCUMENTS 
EP 
EP 
0 036 776 
0 073 657 
5/1988 
12/1990 
(Continued) 
OTHER PUBLICATIONS 
del-Rio, J.A. eta!., Plant Cell Reports (1991) vol. 10, pp. 410-413.* 
Letter/Written Disclosure of the Information Disclosure Statement 
for the above-referenced application, mailed herewith Sep. 15, 
2014, 2 pages. 
Allylix, "Protein engineering and chembiosynthesis to produce 
novel sesquiterpenoids," Presentation at BIO World Congress on 
Industrial Biotechnology & Bioprocessing, Washington, D.C. (Jun. 
28, 2010). 
Altschul, "Amino acid substitution matrices from an information 
theoretic perspective," J. Mol. Bioi. 219(3):555-565 (1991). 
ATCC Accession No. CCL 70, derived from CV-1 cell line, Deposi-
tor: Jensen, F., Retrieved from the Internet:<URL:atcc.org/ ATC-
CAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx, 
[accessed Feb. 25, 20ll; 4 pages]. 
ATCC Accession No. CCL 163, Depositor: Aaronson, S., Retrieved 
from the Internet:<URL:atcc.org/ ATCCAdvancedCatalogSearch/ 
ProductDetails/tabid/452/Default.aspx, [accessed Feb. 25, 20ll; 3 
pages]. 
(Continued) 
Primary Examiner- Russell Kallis 
(74) Attorney, Agent, or Firm- McDonnell Boehnen 
Hulbert & Berghoff LLP 
(57) ABSTRACT 
The invention relates to sesquiterpene synthases and meth-
ods for their production and use. Particularly, the invention 
provides nucleic acids comprising the nucleotide sequence 
of citrus valencene synthase (CVS) which codes for at least 
one CVS. The invention further provides nucleic acids 
comprising the nucleotide sequence coding for amino acid 
residues forming the tier 1 and tier 2 domains of CVS. The 
invention also provides for methods of making and using the 
nucleic acids and amino acids of the current invention . 
9 Claims, 13 Drawing Sheets 
US 9,534,237 B2 
Page 2 
(56) References Cited 
U.S. PATENT DOCUMENTS 
2007/0089198 A1 4/2007 Chappell. 800/280 
2007/0231861 A1 10/2007 Millis eta!. ................. 435/69.1 
2007/0238157 A1 10/2007 Millis eta!. .................. 435/166 
2007/0238159 A1 10/2007 Millis eta!. ............. 435/252.33 
2007/0238160 A1 10/2007 Millis eta!. ............. 435/252.33 
2007/0254354 A1 1112007 Millis eta!. ............. 435/252.33 
2008/0178354 A1 7/2008 Chappell. 800/298 
2008/0213832 A1 9/2008 Schalk ......................... 435/69.1 
2008/0233622 A1 9/2008 Julien ........................... 435/148 
2010/0035329 A1 2/2010 Millis eta!. ............... 435/254.2 
2010/0120110 A1 5/2010 Chappell ....................... 435/166 
2010/0129306 A1 5/2010 Julien ............................. 424/65 
2010/0151519 A1 6/2010 Julien .......................... 435/69.1 
2010/0151555 A1 6/2010 Julien ........................... 435/193 
2010/0216186 A1 8/2010 Chappell ...................... 435/69.1 
201110081703 A1 4/2011 Chappell ....................... 435/193 
201110318797 A1 12/2011 Chappell ....................... 435/155 
2012/0196340 A1 8/2012 Chappell ....................... 435/148 
2013/0071877 A1 3/2013 Chappell ......................... 435/41 
2013/0330793 A1 12/2013 Chappell ....................... 435/155 
2014/0212939 A1 7/2014 Chappell ...................... 435/69.1 
2014/0242658 A1 8/2014 Julien et al. ................. 435/69.1 
2014/0242660 A1 8/2014 Chappell ....................... 435/468 
FOREIGN PATENT DOCUMENTS 
EP 
wo 
wo 
wo 
wo 
wo 
wo 
wo 
wo 
wo 
1 033 076 
wo 97/38703 
wo 99/37139 
wo 00/17327 
wo 02/072758 
wo 03/025193 
wo 2004/031376 
wo 2005/021705 
wo 2006/079020 
wo 2010/019696 
9/2000 
10/1997 
7/1999 
3/2000 
9/2002 
3/2003 
4/2004 
3/2005 
7/2006 
212010 
OTHER PUBLICATIONS 
ATCC Accession No. CCL 10™, Depositor: Macpherson, I., 
Retrieved from the Internet:<URL:atcc.org/ ATC-
CAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx, 
[accessed Feb. 27, 2011; 3 pages] 
ATCC Accession No. CRL 1651, Cell Type: SV40 transformed, 
Depositor: Gluzman, Y., Retrieved from the Internet: <URL:atcc. 
org/ ATCCAdvancedCatalogSearch/ProductDetails/tabid/45 2/De-
fault.aspx, [accessed Feb. 25, 2011; 4 pages]. 
ATCC Accession No. CRL 10478, Depositor: Immunex Corpora-
tion, Retrieved from the Internet:<URL:atcc.org/ ATC-
CAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx, 
[accessed Feb. 25, 2011; 4 pages]. 
ATCC Accession No. 37092, Depositor: Bernard, H., Retrieved 
from the Internet:<URL:atcc.org/ ATCCAdvancedCatalogSearch/ 
ProductDetails/tabid/452/Default.aspx, [accessed Apr. 28, 2010; 2 
pages]. 
ATCC Accession No. 53082, Depositors: Immunex Corporation and 
S.Gillis., Retrieved from the Internet:<URL:atcc.org/ ATC-
CAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx, 
[Apr. 28, 2010; 2 pages]. 
Back et al., "Expression of a plant sesquiterpene cyclase gene in 
Escherichia coli," Arch. Biochem. Biophys. 315:527-532 (1994). 
Back, K. and J. Chappell, "Cloning and bacterial expression of a 
sesquiterpene cyclase from Hyoscyamus muilcus and its molecular 
comparison to related terpene cyclases," J. Bioi. Chern. 270:7375-
7381 (1995). 
Back, K. and J. Chappell, "IdentifYing functional domains within 
terpene cyclases using a domain-swapping strategy," Proc. Nat!. 
Acad. Sci. U.S.A. 93:6841-6845 (1996). 
Back et a!., "Cloning of a sesquiterpene cyclase and its functional 
expression by domain swapping strategy," Mol. Cells 10:220-225 
(2000). 
Bauer et a!., "A genetic enrichment for mutations constructed by 
oligodeoxynucleotide-directed mutagenesis," Gene 37:73-81 
(1985). 
Beier, D. and E. Young, "Characterization of a regulatory region 
upstream of the ADR2 locus of S. cerevislae," Nature 300:724-728 
(1982). 
Calvert et al., "Germacrene A is a product of the aristolochene 
synthase-mediated conversiOn of farnesylpyrophosphate to 
aristolochene," J. Am. Chern. Soc. 124:11636-11641 (2002). 
Cane, D., "Enzymatic formation of sesquiterpenes," Chern. Rev. 
90:1089-1103 (1990) . 
Chang eta!., "Phenotypic expression in E. coli of a DNA sequence 
coding for mouse dihydrofolate reductase," Nature 275:617-624 
(1978) . 
Chappell, J., "Biochemistry and molecular biology of the isoprenoid 
biosynthetic pathway in plants," Annu. Rev. Plant Physiol. Plant 
Mol. Bioi. 46:521-547 (1995) . 
Chappell et al., "Is the reaction catalyzed by 3-hydroxy-3-
methylglutaryl coenzyme A reductase a rate-limiting step for 
isoprenoid biosynthesis in plants," Plant Physiol. 109:1337-1343 
(1995) . 
Chappell, J., "The biochemistry and molecular biology of 
isoprenoid metabolism," Plant Physiol. 107:1-6 (1995) . 
Chappell, J., "The genetics and molecular genetics of terpene and 
sterol origami," Curr. Opin. Plant Bioi. 5:151-157 (2002). 
Chappell, J., "Valencene synthase-a biochemical magician and 
harbinger of transgenic aromas," Trends Plant Sci. 9(6):266-269 
(2004). 
Craik, C., "Use of oligonucleotides for site-specific mutagenesis," 
BioTechniques 3(1): 12-19 (1985). 
Deguerry et a!., "The diverse sesquiterpene profile of patchouli, 
Pogosteinon cab/in, is correlated with a limited number of 
sesquiterpene synthases," Arch. Biochem. Biophys. 454:123-136 
(2006). 
Dolan, K., "Allylix sniffs out biotech for new fragrances," found in 
Forbes Magazine dated Nov. 8, 2010, Published on Oct. 21, 2010 
[online][retrieved on Jun. 1, 2012] Retrieved from:<URL:forbes. 
corn/forbes/20 10/11 08/technology-allylix-fragrances-flavor-caro-
lyn-fritz-smell-test.html?partneFemail [1 page]. 
Drawert et a!., "Regioselective biotransformation of valencene in 
cell suspension cultures of Citrus sp.," Plant Cell Reports 3:37-40 
(1984). 
El Tamer et a!., "Domain swapping of Citrus limon monoterpene 
synthases: impact on enzymatic activity and product specificity," 
Arch. Biochem. Biophys. 411:196-203 (2003). 
Eyal, E., "Computer modeling of the enzymatic reaction catalyzed 
by 5-epi-aristolochene cyclase," Masters Thesis, Department of 
Plant Sciences, Weizmann Institute of Science, Rehovot, Israel (Jan. 
2001) [44 pages]. 
Facchini, P. and J. Chappell, "Gene family for an elicitor-induced 
sesquiterpene cyclase in tobacco," Proc. Nat!. Acad. Sci. U.S.A. 
89:11088-11092 (1992). 
Fleer et a!., "High-level secretion of correctly processed recombi-
nant human interleukin-1 i3 in Kluyveromyces lac tis," Gene 107:285-
295 (1991). 
GenBank Accession No. AF288465, "Citrus junos terpene synthase 
mRNA, complete cds," Retrieved from the Internet:<URL:ncbi. 
nlm.nih.gov/nucore/9864188, Published on Aug. 22, 2000. 
[accessed Feb. 25, 2011] [2 pages]. 
Genbank Accession No. AF411120 [online], "Citrus x paradisi 
putative terpene synthase mRNA, complete cds," Published on Apr. 
2, 2002 [retrieved on Feb. 25, 2011] [retrieved from the 
Internet:<URL:ncbi.nlm.nih.gov/nuccore/ AF411120] [2 pages]. 
GenBank Accession No. AAM00426.1, "putative terpene synthase 
[Citrus x paradisi]," Retrieved from the Internet<URL:ncbi.nlm. 
nih.gov/protein/ AAM00426.1, Published on Apr. 2, 2002. [accessed 
Jan. 4, 2012] [2 pages]. 
GenBank Accession No. AAQ04608.1 (AF441124_1), valencene 
synthase [Citrus sinensis], Retrieved from the Internet:<URL:ncbi. 
nlm.nih.gov/protein/33316389, Published on Jan. 12, 2004. 
[accessed Mar. 21, 2012 [1 page]. 
US 9,534,237 B2 
Page 3 
(56) References Cited 
OTHER PUBLICATIONS 
GenBank Accession No. ACK18099, "Sequence 4 from U.S. Pat. 
No. 7,442,785," Retrieved from the Internet<URL:ncbi.nlm.nih. 
gov/protein/ACK18099, Published on Dec. 10, 2008. [accessed 
Feb. 25, 20ll] [2 pages]. 
GenBank Accession No. ACX70155.1, "terpene synthase 1 [Citrus 
sinensis]," Retrieved from the Internet:<URL:ncbi.nlm.nih.gov/ 
protein/ACX70155.1, Published on Oct. 20, 2009. [accessed Feb. 
25, 20ll] [2 pages]. 
Gluzman, Y., "SV40-transformed simian cells support the replica-
tion of early SV40 mutants," Cell23(1):175-182 (1981). 
Goedde! et a!., "Direct expression in Escherichia coli of a DNA 
sequence coding for human growth hormone," Nature 281:544-548 
(1979). 
Goedde! eta!., "Synthesis of human fibroblast interferon by E. coli," 
Nucleic Acids Res. 8:4057-4074 (1980). 
Greenhagen, B. and J. Chappell, "Molecular scaffolds for chemical 
wizardry: learning nature's rules for terpene cyclases," Proc. Nat!. 
A cad. Sci. U.S.A. 98: 13479-13491 (200 1 ). 
Greenhagen et a!., "Probing sesquiterpene hydroxylase activities in 
a coupled assay with terpene synthases," Arch. Biochem. Biophys. 
409:385-394 (2003). 
Greenhagen, B., "Origins of isoprenoid diversity: A study of struc-
ture-function relationships in sesquiterpene synthases," Disserta-
tion, College of Agriculture at the University of Kentucky (2003) 
[163 pages]. 
Greenhagen et a!., "identifYing and manipulating structural deter-
minates linking catalytic specificities in terpene synthases," Proc. 
Nat!. Acad. Sci. U.S.A. 103:9826-9831 (2006). 
Hess et a!., "Cooperation of glycolytic enzymes," Adv. Enzyme 
Reg. 7:149-167 (1969). 
Hitzeman et a!., "Isolation and characterization of the yeast 
3-phosphoglycerokinase gene (PGK) by an immunological screen-
ing technique," J. Bioi. Chern. 255:12073-12080 (1980). 
Holland, M. and J. Holland, "Isolation and identification of yeast 
messenger ribonucleic acids coding for enolase, glyceraldehyde-3-
phosphate dehydrogenase, and phosphoglycerate kinase," Biochem. 
17:4900-4907 (1978). 
Hunter eta!., "Conversion ofvalencene to nootkatone," J. Food Sci. 
30(5):876-878 (1965). 
Joly, A. and P. Edwards, "Effect of site-directed mutagenesis of 
conserved aspartate and arginine residues upon farnesyl 
diphosphate synthase activity," J. Bioi. Chern. 268:26983-26989 
(1993). 
Kunkel, T, "Rapid and efficient site-specific mutagenesis without 
phenotypic selection," Proc. Nat!. Acad. Sci. U.S.A. 82:488-492 
(1985). 
Kunkel et a!., "Rapid and efficient site-specific mutagenesis without 
phenotypic selection," Meth. Enzymol. 154:367 (1987). 
Laskovics, F. and C. Poulter, "Prenyltransferase: determination of 
the binding mechanism and individual kinetic constants for 
farnesylpyrophosphate synthetase by rapid quench and isotope 
partitioning experiments," Biochem. 20:1893-1901 (1981). 
Lee, S. and J. Chappell, "Biochemical and genomic characterization 
of terpene synthases in Magnolia grandiflora," Plant Physiol. 
147:1017-1033 (2008). 
Louzada et a!., "Isolation of a terpene synthase gene from mature 
"Rio Red" grapefruit using differential display," Program Schedule 
and Abstracts for the 98th Annual International Conference of the 
American Society for Horticultural Science, Sacramento, CA, Jul. 
22-25, 2001, HortScience 36(3):425-444 (2001). 
Louzada et a!., "Isolation of a terpene synthase gene from mature 
"Rio Red" grapefruit using differential display," Program Schedule 
and Abstracts for the 98th Annual International Conference of the 
American Society for Horticultural Science, Sacramento, CA, Jul. 
22-25, 2001, HortScience 36(3):440 (2001). 
Luckow, V. and M. Sununers, "Trends in the development of 
baculovirus expression vectors," Nature Biotechnol. 6:47-55 
(1988). 
Maniatis et a!., "Molecular Cloning: A Laboratory Manual," Cold 
Spring Harbor Laboratory, p. 412 (1982). 
Maruyama et a!., "Molecular cloning, functional expression and 
characterization of (E)-!3-farnesene synthase from Citrus junos," 
Bioi. Pharm. Bull. 24(10):ll71-ll75 (2001). 
Mathis eta!., "Pre-steady-state study of recombinant sesquiterpene 
cyclases," Biochem. 36:8340-8348 (1997). 
Newman et a!., "Characterization of the TAC box, a cis-element 
within a elicitor-inducible sesquiterpene cyclase promoter," Plant J. 
16:1-12 (1998). 
Newman, J. and J. Chappell, "Isoprenoid biosynthesis in plants: 
carbon partitioning within the cytoplasmic pathway," Crit. Rev. 
Biochem. Mol. Bioi. 34:95-106 (1999). 
Ohnuma eta!., "A role of the amino acid residue located on the fifth 
position before the first aspartate-rich motif of farnesyl diphosphate 
sythase of determination of the final product," J. Bioi. Chern. 
271:30748-30754 (1996). 
O'Maille eta!., "Biosynthetic potential of sesquiterpene synthases: 
alternative products of tobacco 5-epi-aristolochene synthase," Arch. 
Biochem. Biophys. 448:73-82 (2006). 
Phys.org, "Substance that gives grapefruit its flavor and aroma 
could give insect pests the boot," found on Phys.org dated Sep. ll, 
2013 [online][retrieved on Nov. 19, 2013] Retrieved 
from: <URL :phys. org/ news/2 0 13 -09 -substance-grapefruit-flavor-
aroma-insect.htrnl [2 pages]. 
Proctor, R. and T. Hohn, "Aristolochene synthase. Isolation, char-
acterization, and bacterial expression of a sesquiterpenoid 
biosynthetic gene (Ari[) from Penicillium roqueforti," J. Bioi. 
Chern. 268:4543-4548 (1993). 
Quigley, K., "Allylix raises $18.2M, announces launch of new 
product for fragrance market," San Diego Business Journal, Pub-
lished on Mar. 14, 2012 [online][retrieved on Jun. 1, 2012] 
Retrieved from: <URL: sdbj .corn/news/20 12/mar/ 14/allylix-raises-
182m-announces-launch-new-product-f/ [1 page]. 
Ralston et a!., "Biochemical and molecular characterization of 
5-epi-aristolochene 3-hydroxylase, a putative regulatory enzyme in 
the biosynthesis of sesquiterpene phytoalexins in tobacco," Plant 
Interactions with Other Organisms. Annual Meeting of the Ameri-
can Society of Plant Physiologists. Madison, WI., Jun. 27-Jul. 1, 
1998, Session 47:Abstract #737 (Poster Presentation). 
Ralston et a!., "Cloning, heterologous expression, and fuctional 
characterization of 5 -epi -aristolochene-1 ,3 -dihydroxylase from 
tobacco (Nicotiana tabacum)," Arch. Biochem. Biophys. 393:222-
235 (2001). 
Rising eta!., "Demonstration of germacrene A as an intermediate in 
5-epi-aristolochene synthesis catalysis," J. Am. Chern. Soc. 
122:1861-1866 (2000). 
Russell et a!., "Nucleotide sequence of the yeast alcohol 
dehydrogenase II gene," J. Bioi. Chern. 258:2674-2682 (1982). 
Schalk, M. and R. Croteau, "A single amino acid substitution 
(F363I) converts the regiochemistry of the spearmint (-)-limonene 
hydroxylase from a C6- to a C3-hydroxylase," Proc. Nat!. Acad. Sci. 
U.S.A. 97:ll948-ll953 (2000). 
Schenk et al., "Stereochemistry and deuterium isotope effects 
associated with the cyclization-rearrangements catalyzed by 
tobacco epiaristolochene and hyoscyamus prernnaspirodiene 
synthases, and the chimeric CH4 hybrid cyclase," Arch. Biochem. 
Biophys. 448:31-44 (2006). 
Sharon-Asa et a!., "Citrus fruit flavor and aroma biosynthesis: 
isolation, functional characterization, and developmental regulation 
ofCstps 1, a key gene in the production of the sesquiterpene aroma 
compound valencene," Plant J. 36:664-674 (2003). 
Starks et al., "Structural basis for cyclic terpene biosynthesis by 
tobacco 5-epi-aristolochene synthase," Science 277:1815-1820 
(1997). 
Studier and Moffatt, "Use of bacteriophage T7 RNA polymerase to 
direct selective high-level expression of cloned genes," J. Mol. Bioi. 
189:ll3-130 (1986). 
Thai et a!., "Farnesol is utilized for isoprenoid biosynthesis in plant 
cells via farnesyl pyrophosphate formed by successive 
monophosphorylation reactions," Proc. Nat!. Acad. Sci. U.S.A. 
96:13080-13085 (1999). 
(56) References Cited 
OTHER PUBLICATIONS 
US 9,534,237 B2 
Page 4 
Tholl, D., "Terpene synthases and the regulation, diversity and 
biological roles of terpene metabolism," Curr. Opin. Plant Bioi. 
9(3):297-304 (2006). 
van den Berget a!., "Kluyveromyces as a host for heterologous gene 
expression: expression and secretion of prochymosin," Biotcchnol. 
8:135-139 (1990). 
Walder, R. and J. Walder, "Oligodeoxynucleotide-directed 
mutagenesis using the yeast transformation system," Gene 42:133-
139 (1986). 
Wilson et a!., "Synthesis of nootkatone from valencene," J. Agric. 
Food Chern. 26(6): 1430-1432 (1978). 
Wu eta!., "Redirection of cytosolic or plastidic isoprenoid precur-
sors elevates terpene production in plants," Nat. Biotechnol. 
24:1441-1447 (2006). 
Yin et a!., "Regulation of sesquiterpene cyclase gene expression-
characterization of an elicitor- and pathogen-inducible promoter," 
Plant Physiol. 115:437-451 (1997). 
Zhao et a!., "Eremophilane sesquiterpenes from capsidiol," J. Org. 
Chern. 69:7428-7435 (2004). 
Office Action, issued May 15, 2007, in connection with correspond-
ing U.S. Appl. No. 10/899,356, 17 pages. 
Office Action, issued May 12, 2011, in connection with correspond-
ing U.S. Appl. No. 12/259,497, 8 pages. 
Notice of Allowance, issued Dec. 2, 2011, in connection with 
corresponding U.S. Appl. No. 12/259,497, 7 pages. 
Office Action, issued Dec. 3, 2013, in connection with correspond-
ing U.S. Appl. No. 13/385,794, 6 pages. 
Notice of Allowance, issued May 16, 2014, in connection with 
corresponding U.S. Appl. No. 13/385,794, 5 pages. 
* cited by examiner 
U.S. Patent Jan.3,2017 Sheet 1 of 13 
FIG.1 
14 
15 
US 9,534,237 B2 
OPP 
FPP 
14 
12 
13 
5-EPL- ARISTOLOCHENE 
PREMNASPIRODIENE 
VALENCENE 
U.S. Patent Jan.3,2017 Sheet 2 of 13 US 9,534,237 B2 
FIG. 2 
U.S. Patent 
FIG. 3 
SYNTHASE PRODUCT 
5-EP!-ARISTOLOCHENE 
PREMNASPIRODIENE 
VALENCENE 
Jan.3,2017 Sheet 3 of 13 US 9,534,237 B2 
OPP 
FPP 
VALENCENE NOOTI<ATONE 
FIRST TIER SECOND TIER 
J/KLOOP 
~ ~ ~ ~ ~ *'~ &! ~ &l 0 :g R ~ ~ £:! ~ ~ ~ ~ ~ ; ~ ~"'"' .0'0> g) "' .............. ......... N N N M M ll') It') ll') ll') "' 
R W T y c D y D y T F R c s D V y T T L s R D T L I v T H 
R W T y c D y D y T F R c s DDY TILIR D T L IHT H 
R w~t,~ Y c D y D y T p R~~~ S DVY~] ~~~·RD~~~L~~ T H 
FIG. 4 
U.S. Patent Jan.3,2017 Sheet 4 of 13 US 9,534,237 B2 
NUCLEOTIDE (DNA) SEQUENCE FOR CITRUS VALENCENE SYNTHASE 
GENE (CVS) 
SEQIDNO.: 1 
LENGTH: 1710 NT 
M ATGTCGTCTGGAGAAACATTTCGTCCTACTGCAGATTTCCATCCT 
1~ AGTTTATGGAGAAACCATTTCCTCAAAGGTGCTTCTGATTTCAAG 
1~ ACAGTTGATCATACTGCAACTCAAGAACGACACGAGGCACTGAAA 
1~ GAAGAGGTAAGGAGAATGATAACAGATGCTGAAGATAAGCCTGTT 
2« CAGAAGTTACGCTTGATTGATGAAGTACAACGCCTGGGGGTGGCT 
289 TATCACTTTGAGAAAGAAATAGAAGATGCAATACTAAAATT ATGT 
~ CCAATCTATATTGACACTAATAGAGCTGATCTCCACACCGTTTCC 
379 CTTCATTTTCGATTGATTAGGCAGCAAGGAATCAAGATTTCA TGT 
~4 GATGTGTTTGAGAAGTTCAAAGATGATGAGGGTAGATTCAAGTCA 
469 TCGTTGATAAACGATGTTCAAGGGATGTTAAGTTTGTACGAGGCA 
514 GCAT ACATGGCAGTTCGCGGAGAACAT ATA TTAGATGAAGCCATT 
559 GCTTTCACTACCACTCACCTGAAGTCA TTGGTAGCTCAGGATCAT 
6M GTAACCCCTAAGCTTGCGGAACAGATAAATCATGCTTTATACCGT 
M9 CCTCTTCGTAAAACCCTACCAAGATTAGAGGCGAGGTATTTTATG 
694 TCCATGATCAATTCAACAAGTGATCATTT ATACAATAAAACTCTG 
739 CTGAATTTTGCAAAGTTAGA TTTT AACATATTGCT AGAGCCGCAC 
7M AAGGAGGAACTCAATGAATTAACAAAGTGGTGGAAAGATTTAGAC 
829 TTCACTACAAAACTACCTTATGCAAGAGACAGATTAGTGGAGTTA 
974 TAZTTTTGGGATTT AGGGACATACTTCGAGCCTCAAT ATGCATTT 
919 GGGAGAAAGATAATGACCCAATTAAATTACATATTATCCATCATA 
9M GATGATACTTATGATGCGTATGGTACACTTGAAGAACTCAGCCTC 
1009 TTTACTGAAGCAGTTCAAAGATGGAATATTGAGGCCGT AGATATG 
10~ CTTCCAGAATACATGAAATTGATTTACAGGACACTCTTAGATGCT 
1~9 TTTAATGAAATTGAGGAAGATATGGCCAAGCAAGGAAGATCACAC 
11« TGCGTACGTTATGCAAAAGAGGAGAATCAAAAAGTAATTGGAGCA 
1189 TACTCTGTTCAAGCCAAATGGTTCAGTGAAGGTT ACGTTCCAACA 
1~ ATTGAGGAGTATATGCCTATTGCACTAACAAGTTGTGCTTACACA 
1279 TTCGTCATAACAAATTCCTTCCTTGGCATGGGTGA TTTTGCAACT 
1324 AAAGAGGTTTTTGAATGGATCTCCAAT AACCCTAAGGTGTTAAAA 
1369 GCAGCATCAGTTATCTGCAGACTCATGGATGACATGCAAGGTCAT 
1414 GAGTTTGAGCAGAAGAGAGGACATGTTGCGTCAGCTATTGAATGT 
1459 TACACGAAGCAGCATGGTGTOTCTAAGGAAGAGGCAATTAAAATG 
15M TTTGAAGAAGAAGTTGCAAATGCATGGAAAGATATTAACGAGGAG 
1549 TTGATGATGAAGCCAACCGTCGTTGCCCGACCACTGCTCGGGACG 
1594 A TTCTT AA TCTTGCTCGTGCAATTGATTTT ATTTACAAAGAGGAC 
1~9 GACGGCTATACGCATTCTTACCTAATTAAAGATCAAATTGCTTCT 
1684 G T G C TAG GAG A C C A C G T T C CAT T T T G A 1710 
FIG. 5 
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AMINO ACID SEQUENCE OF CITRUS VALENCENE SYNTHASE (CVS) 
SEQIDN0.:4 
LENGTH; 548 AA 
1 M s s G E T F R p T A D F H p 
16 s L w R N H F L K G A s D F K 
31 T v D H T A T Q E R H E A L K 
46 E E v R R M I T D A E D K p v 
61 Q K L R L I D E v Q R L G v A 
76 y H F E K E I E D A I L K L c 
91 p I y I D s N R A D L H T v s 
106 L H F R L L R Q Q G I K I s c 
121 D v F E K F K D D E G R F K s 
136 s L I N D v Q G M L s L y E A 
151 A y M A v R G E H I L D E A I 
166 A F T T T H L K s L v A Q D H 
181 v T p K L A E Q I N H A L y R 
196 p L R K T L p R L E A R y F M 
211 s M I N s T s D H L y N K T L 
226 L N F A K L D F N I L L E p H 
241 K E E L N E L T K WWD D L D 
256 F T T K L p y A R D R L v E L 
271 y F w D L G T y F E p Q y A F 
286 G R K I M T Q L N y I L s I I 
301 D D T y D A y G T L E E L s L 
316 F T E A v Q R w N I E A v D M 
331 L p E y M K L I y R T L L D A 
346 F N E I E E D M A K Q G R s H 
361 c v R y A K E E N Q K V I G A 
376 y s v Q A K w F s E G Y v p T 
391 I E E y M p I A L T S C A y T 
406 F v I T N s F L G MGD F A T 
421 K E v F E w I s N N P K v v K 
436 A A s v I c R L M DDM Q G H 
451 E F E Q K R G H v A S A I E c 
466 y T K Q H G v s K E E A I K M 
481 F E E E v A N A w K D I N E E 
496 L M M K p T v v A R p L L G T 
511 I L N L A R A I D F I y K E D 
526 D G y T H s y L I K D Q I A s 
541 v L G D H v p F .. 548 
FIG. 6 
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ABSOLUTE SEQ ID NO 4 COMPARATIVE SEQ ID NO 8 NUCLEOTIDE SEQ ID NO.: 6 
F13 F20 100ttc 
R266 R266 859aga 
1.270 1.270 871tta 
S298 S298 955tcc 
0302 0302 967gat 
V372 V372 1177gta 
Y376 Y376 1189tac 
8401 5401 I264agt 
C2402 C402 1267tgt 
V407 V407 1282gtc 
A437 A436 1372gca 
R442 R441 1387aga 
0446 0445 1399gac 
G449 6448 1408ggt 
l514 L512 1603ctt 
A517 A515 1612gca 
1518 1516 1615att 
1521 1519 1624att 
H530 H529 1651cat 
FIG.13 
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MASAA VANYEBEIVRPVADFSPSLWGDQFLS--FSIKNQVAEKY AQEIEA 48 
MSSG-------ETFRPT ADFHPSL WRNHFLKGASDFKTVDHTA TQERHE 43 
LKEQTRNMLLATGMKLADTLNLIDTIERLGISYHFEKEIDDILDQIYNQ- 97 
LKEEVRRMITDAEDKPVQKLRLIDEVQRLGV A YHFEKEIEDAILKLCPIY 93 
-NSCNDLCTSALQFRLLRQHGFNISPEIFSKFQDENGKFKESLASDVLG 146 
IDSNRADLHTVSLHFRLLRQQGIKISCDVFEKFKDDEGRFKSSLINDVQG 143 
LLNL YEASHVRTHADDILEDALAFSTIHLES--AAPHLDSPLREQVTHA L 194 
MLSL YEAA YMA VRGEHILDEAIAFTTTHLKSL VAQDHVTPKLAEQINHA L 193 
EQCLHKGVPRVETRFFISSIYDKE-QSKNNVLLRFAKLDFNLLQMLHKQE 243 
YRPLRKTLPRLEARYFMSMINSTSDHLYNKTLLNFAKLDFNILLEPHKEE 243 
LAQVSRWWKDLDFVTTLPY AjRpRVVECY~LGVYFEPQYSQARVML VKT r;93 
LNELTKWWKDLDFTTKLPY ~RL VEL Y~LGTYFEPQY AFGRKIMTQL ~ 
ISISIVDDTRDA YGTVKELEAYTDAIQRWDINEIDRLPDYMKISYKAIL .343 
NYILSIIDDTYDAYGTLEELSLFTEAVQRWNIEAVDMLPEYMKLIYRTLL .343 
DL YKDYEKELSSAG RSHIVCHAIERMKEVVRNYNVESTWFIEGYTPPVSE 393 
DAFNEIEEDMAKQGRSHCVRYAKEtNQKVIGA YSVQAKWFSEGYVPTIEE 393 
YLSN ALA T~YYLA TTSYLGMKS-A TEQDFEWLSKNPKILEAS VI~ V ~ 
YMPIALTSC~FVITNSFLGMGDFATKEVFEWISNNPKVVKAAS~L ~ 
IP\xATYEVEKSRGQIA TGIECCMRDYGISTKEAMAKFQNMAETAWDIN 492 
MfPMQGHEFEQKRGHV ASAIECYTKQHGVSKEEAIKMFEEEV ANAWKDIN 493 
EGLLRJPTPVSTEFLTPILNLARJ~: IY$rEKVLKVLKPHIINL 541 
EBLMMKPTVVARPLLGTILNLARAID I KE <t:1Ht1-SYLIKDQIASV 541 
LVDSIKIN 549 
LGDHVPF- 548 
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TEAS AMINO CVS ABSOLUTE COMPARATIVE 
ACID NUMBER SEQIDN0.:4 SEQ ID NOS 7 AND 8 
TIER1 
R264 R264 R264 
W273 W273 W273 
T403 A403 A403 
Y404 Y404 Y404 
C440 C441 C440 
D444 0445 0444 
Y520 Y522 Y520 
0525 0526 0525 
Y527 Y528 Y527 
T528 T529 T528 
TIER2 
F20 F13 F20 
R266 R266 R266 
C270 L270 L270 
5298 5298 5298 
0302 0302 0302 
V372 V372 V372 
Y376 Y376 Y376 
T401 5401 5401 
T402 C402 C402 
L407 V407 V407 
5436 A437 A436 
R441 R442 R441 
0445 D446 D445 
T448 G449 0448 
L512 LL514 L512 
I515 A517 A515 
V516 1518 1516 
T519 1521 1519 
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SESQUITERPENE SYNTHASE GENE AND 
PROTEIN 
RELATED APPLICATIONS 
2 
This application is a continuation of U.S. patent applica-
tion Ser. No. 13/385,794, filed Mar. 6, 2012, now allowed, 
which is a continuation of U.S. patent application Ser. No. 
12/259,497, filed Oct. 28, 2008, now U.S. Pat. No. 8,192, 
950, issued Jun. 5, 2012, which is a continuation of U.S. 
patent application Ser. No. 10/899,356, filed on Jul. 26, 
2004, now U.S. Pat. No. 7,442,785, issued Oct. 28, 2008, 
which claims benefit of priority to U.S. Provisional Appli-
cation No. 60/489,514, filed Jul. 24, 2003. The subject 
matter of each of the above-referenced applications is herein 15 
incorporated by reference in its entirety. 
natural orange essence oil with a solvent gas having a 
temperature between its critical temperature and 100° C., 
and having a reduced pressure between about 0.56 and about 
1.31 (where reduced pressure is defined as the extraction 
pressure of the solvent gas divided by its critical pressure), 
to extract flavor and aroma compounds; (b) separating the 
solvent gas and dissolved compounds from the remaining 
undissolved compounds; and (c) separating the dissolved 
compounds from the solvent gas. 
10 Rich, in U.S. Pat. No. 4,973,485, discloses a method of 
producing aqueous orange stripper essences and orange 
stripper oils with high ratios of valencene to the less desir-
able orange flavor compounds. This procedure involves the 
following steps: (a) heating an orange fed juice stream to a 
temperature of37.7° C. to 71° C.; (b) stripping the heated 
feed juice with steam at a steam: soluble solids ratio of 0.3 
to 1.5, at a temperature of 37.7° C. to 71 o C. and at a 
stripping colunm pressure of less than 9 inches of Hg, 
FIELD OF THE INVENTION 
This invention relates generally to the field of production 
of valencene and nootkatone, and more particularly relates 
to the discovery of a valencene synthase gene and related 
protein, which provides a pathway for generating highly 
pure valencene which can be converted into the flavorant, 
nootkatone. 
BACKGROUND 
Terpenes are a diverse family of compounds with carbon 
skeletons composed of five-carbon isoprene units. Approxi-
mately 20,000 different terpenes and terpenoids (compounds 
of terpene origin whose carbon skeleton has been altered or 
rearranged) have been identified to date, representing only a 
small fraction of the estimated natural variation. Terpenes 
are commonly isolated from the essential oils of plants. 
Essential oils often have pleasant tastes or aromas, and they 
are widely used as flavorings, deodorants, and medicines. 
20 absolute; (c) condensing the stripped volatiles at a tempera-
ture of 40.6° C. to -196° C.; (d) centrifuging the condensate 
in a continuous stacked disk hermetic centrifuge to produce 
two clear phases; and (e) removing the aqueous orange 
25 
stripper essence phase. 
In U.S. Pat. No. 5,260,086 Downton et a!. describe a 
process for making an aseptic citrus sensible pulp/juice 
slurry by extracting and removing juice from citrus juice 
containing sensible pulp. After this process is complete, 
flavorants, such as valencene are added to make up for those 
30 that are lost during this extraction process. 
Hiramoto et a!., in U.S. Pat. No. 6,495,193 prepares a 
citrus flavor from a low-boiling part of a cold pressed oil by 
a hydrate alcohol solvent extraction. To maintain the stabil-
ity of the flavor, a stabilizing coumarin analogue component 
35 is added. 
Sesquiterpenes are terpenes with 15 carbon atoms (three 
isoprene units). The plant kingdom contains the highest 
diversity of sesquiterpenes. Often they play a role in defense 40 
of the plants against pathogens, insects and herbivores and 
for attraction of pollinating insects. 
In a US Patent Application, publication number US 
20030185956, Gradley claims a separation method for 
extracting desired sesquiterpene aroma compounds, such as 
valencene and nootkatone, from an aqueous phase by sepa-
rating the aqueous mixture from a water-immiscible hydro-
phobic phase by means of a hydrophilic membrane and 
allowing the desired components to move out off the aque-
ous phase through the membrane and into the hydrophobic 
phase. 
Valencene (1,2,3,5,6,7,8,8a-octahydro-7 -isopropenyl-1, 
Sa-dimethyl-naphthalene) and nootkatone (4,4a,5,6,7,8-
hexahydro-6-isopropenyl-4,4a-dimethyl-2(3H)-naphtal-
enone) are just two examples of sesquiterpenes that are 
derived from cyclization of the ubiquitous pyrophosphate 
intermediate farnesyl diphosphate. Nootkatone is formed by 
the oxidation of valencene. 
Valencene and nootkatone are compounds of natural 
origin, and are natural constituents of citrus oils, such as 
orange and grapefruit. Because of its excellent organoleptic 
qualities and in particular its typical grapefruit taste, noot-
katone is a widely used ingredient in perfumery and the 
flavor industry. Alternatively, nootkatone may be used as an 
insecticide. Valencene, the starting material for the genera-
tion of nootkatone (either biologically or chemically), is also 
used as a flavorant and fragrance. 
Several methods to purify sesquiterpenes, such as valen-
cene and nootkatone, from citrus fruits or to maintain high 
levels of these sesquiterpenes in citrus fruit extracts have 
been described in the prior art. These methods are described 
below. 
Japikse et a!., in U.S. Pat. No. 4,693,905, claimed a 
method of extracting concentrated orange flavor and aroma 
compositions from natural orange essence oil by using a 
dense solvent gas. Their procedure entailed (a) contacting 
45 Kotachi et a!., in US Patent Application, publication 
number 20030203090, teaches of a process for preparing 
orange oil useful as fragrance or flavor material, by mixing 
raw material oil containing valencene with a high-boiling 
solvent having a boiling point exceeding 240° C. under 
50 normal pressure, to give a mixture, and fractionally distilling 
the mixture obtained. 
Nootkatone is a high demand, high value flavorant added 
to many of the commercial soft drinks sold worldwide. 
Currently, the practice of extracting nootkatone from citrus 
55 pulp and rind is considered an expensive and somewhat 
unreliable process. Nootkatone can be synthesized by the 
oxidation of valencene. The valencene starting material is 
expensive and is easily degraded during evaporative heat 
concentration processes typically used to remove the bulk of 
60 water from the feed juice. Thus, current methods to purifY 
valencene from citrus fruits are costly, difficult, and are 
limited by what the fruit can deliver. Moreover, such meth-
ods are vulnerable to interruptions in the supply of citrus 
fruits, which is dependent on the weather. A frost or hail-
65 storm in a major citrus fruit growing region such as Florida 
can interrupt the supply. Furthermore, methods to produce 
nootkatone that consume valencene are quite costly, and thus 
US 9,534,237 B2 
3 
not connnercially desirable. Therefore, there is a need for an 
alternative means for preparing valencene and nootkatone. 
SUMMARY OF THE INVENTION 
In one embodiment, the invention relates to isolated 
nucleic acids that encode a sesquiterpene synthase. The 
invention provides an isolated nucleic acid selected from: (a) 
4 
sequence under conditions conducive to the production of 
said at least one sesquiterpene synthase. In one embodiment, 
the at least one nucleic acid is chosen from (a) a nucleic acid 
comprising the nucleotide sequence substantially as set out 
in SEQ ID N0:1, SEQ ID NO.: 5 or SEQ ID NO.: 6; (b) a 
nucleic acid encoding the polypeptide substantially set out in 
SEQ ID NO: 4, SEQ ID NO.: 7 or SEQ ID NO.: 8; and (c) 
a nucleic acid that hybridizes to the nucleic acid of (a) or (b) 
under low stringency conditions, wherein the polypeptide a nucleic acid comprising the nucleotide sequence substan-
tially as set out in SEQ ID NO: 1; (b) a nucleic acid encoding 
the polypeptide substantially set out in SEQ ID NO: 4; and 
10 encoded by said nucleic acid is a sesquiterpene synthase. 
(c) a nucleic acid that hybridizes to the nucleic acid of (a) or 
(b) under low stringency conditions, wherein the polypep-
tide encoded by said nucleic acid is a sesquiterpene syn-
thase. Other embodiments include: a polypeptide encoded 15 
by a nucleic acid of the invention; a host cell comprising a 
nucleic acid of the invention; a non-human organism modi-
fied to harbor a nucleic acid of the invention; and methods 
of producing a polypeptide comprising culturing host cells 
of the invention. 
In another embodiment, the invention provides an isolated 
polypeptide comprising an amino acid sequence substan-
tially as set out in SEQ ID NO: 4. 
20 
In a further embodiment, the invention provides a vector 
comprising at least one nucleic acid chosen from (a) a 25 
nucleic acid comprising the nucleotide sequence substan-
tially as set out in SEQ ID NO: 1; (b) a nucleic acid encoding 
the polypeptide substantially set out in SEQ ID NO: 4; and 
The host may be chosen from, for example, plants, micro-
organisms, bacterial cells, yeast cells, plant cells, and animal 
cells. 
In another embodiment the invention provides a method 
of making at least one terpenoid comprising: 
1) contacting at least one acyclic pyrophosphate terpene 
precursor with at least one polypeptide encoded by a 
nucleic acid of the current invention. In one embodiment, 
the nucleic acid is chosen from (a) a nucleic acid com-
prising the nucleotide sequence substantially as set out in 
SEQ ID NO.: 1, SEQ ID NO.: 5 or SEQ ID NO.: 6; (b) 
a nucleic acid encoding the polypeptide substantially set 
out in SEQ ID NO: 4, SEQ ID NO.: 7 or SEQ ID NO.: 8; 
and (c) a nucleic acid that hybridizes to the nucleic acid 
of (a) or (b) under low stringency conditions, wherein the 
polypeptide encoded by said nucleic acid is a sesquiter-
pene synthase, 
2) isolating at least one terpenoid produced in 1). 
(c) a nucleic acid that hybridizes to the nucleic acid of (a) or 
(b) under low stringency conditions, wherein the polypep-
tide encoded by said nucleic acid is a sesquiterpene syn-
thase. Other embodiments include, methods of making a 
recombinant host cell comprising introducing a vector of the 
invention into a host cell. 
In one embodiment, the at least one terpenoid is chosen 
30 from the group consisting of sesquiterpene. 
In a further embodiment, the at least one acyclic pyro-
phosphate terpene precursor is farnesyl-diphosphate (FPP). 
The sesquiterpene produced by the methods of the invention 
include, but are not limited to, valencene, valencene deriva-
In a further embodiment, the invention relates to isolated 
nucleic acids that encode a sesquiterpene synthase. The 
invention provides an isolated nucleic acid selected from: (a) 
35 tives, valencene fragments, and compounds having the citrus 
valencene carbon skeleton. 
a nucleic acid comprising the nucleotide sequence substan-
tially as set out in SEQ ID NO: 5 or SEQ ID NO.: 6; (b) a 
nucleic acid encoding the polypeptide substantially set out in 40 
SEQ ID NO: 7 or SEQ ID NO.: 8; and (c) a nucleic acid that 
hybridizes to the nucleic acid of (a) or (b) under low 
stringency conditions, wherein the polypeptide encoded by 
said nucleic acid is a sesquiterpene synthase. Other embodi-
ments include: a polypeptide encoded by a nucleic acid of 45 
the invention; a host cell comprising a nucleic acid of the 
invention; a non-human organism modified to harbor a 
nucleic acid of the invention; and methods of producing a 
polypeptide comprising culturing host cells of the invention. 
In another embodiment, the invention provides an isolated 50 
polypeptide comprising an amino acid sequence substan-
tially as set out in SEQ ID NO: 7 or SEQ ID NO.: 8. 
In a further embodiment, the invention provides a vector 
comprising nucleic acid chosen from (a) a nucleic acid 
comprising the nucleotide sequence substantially as set out 55 
in SEQ ID NO: 5 or SEQ ID NO.: 6; (b) a nucleic acid 
encoding the polypeptide substantially set out in SEQ ID 
NO: 7 or SEQ ID NO.: 8; and (c) a nucleic acid that 
hybridizes to the nucleic acid of (a) or (b) under low 
stringency conditions, wherein the polypeptide encoded by 60 
said nucleic acid is a sesquiterpene synthase. Other embodi-
ments include, methods of making a recombinant host cell 
comprising introducing a vector of the invention into a host 
cell. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the conversion of FPP to the sesquiterpene 
reaction products 5-epi-aristolochene, premnaspirodiene 
and valencene catalyzed by Nicotiana tabacum epi-aristo-
lochene synthase (TEAS), Hyoscyamus muticus prem-
naspirodiene synthase (HPS), and Citrus paradisi valencene 
synthase (CVS), respectively. 
FIG. 2 illustrates a mechanism for the enzyme catalyzed 
development of regia- and enantio-specificity in eremophi-
lanes. Upon loss of the diphosphate from C1 and generation 
of the initial carbocation, a chiral center arises from the first 
attack on either the si or re face of sp2 hybridized C10 
yielding either (1 OR)-germacrene A or (10S)-germacrene A. 
Two additional chiral centers develop upon formation of an 
internal bond between C2 and C7. This process of proton-
initiated, internal cyclization (illustrated as transition states) 
requires that the p-orbitals of sp2 hybridized C2 and C7 face 
and align with each other. The 4 possible combinations of 
overlapping orbitals are dependent on the orientation of the 
respective p orbitals either above or below the plane of the 
eudesmalyl carbocation intermediate. The possible re and si 
orientations of the C2 p-orbitals are given on the vertical 
axis of the diagram and those for C7 depicted on the 
horizontal axis. These orientations direct the stereochemis-
try of the ensuing methyl migrations and hydride shifts (not 
illustrated) and define, as a consequence, the final chirality 
In one embodiment, the invention provides a method of 
making at least one sesquiterpene synthase comprising cul-
turing a host cell modified to contain at least one nucleic acid 
65 of the methyl substitutions at C2 and C3. Subsequent to 
these rearrangements, a tertiary carbocation centered at C7 
is formed (an eremophilyl cation, not shown) and alternate 
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elimination of a proton from C6 or C8 give two subclasses 
of double bond regioisomers, illustrated as layers. Known 
eremophilanes are noted by their common name. 
FIG. 3 illustrates a proposed pathway for the biosynthesis 
of nootkatone in citrus. The scheme suggests at least two 
steps, the first step is catalyzed by the sesquiterpene synthase 
6 
thases were initially identified by primary sequence align-
ment, then visual inspection of the relevant sequences over-
laid on the TEAS 3-dimensional structure. Residues in CVS 
differing from TEAS are highlighted. 
FIG. 12 shows SEQ ID NO.: 5, which is the DNA 
sequence from SEQ ID NO.: 1 corresponding to the amino 
acids forming Tier 1. Comparative numbering from Tier 1 
amino acid residues is also shown (SEQ ID NO.: 7). 
of the current invention, denoted as "1" in the figure, which 
leads to the production of valencene and the second step 
consisting of a regia-specific hydroxylation, followed by 
oxidation. The second step could be catalyzed by a single 
multifunctional hydroxylase or could involve sequential 
enzyme mediated reactions, and which are denoted as "2" in 
the figure. 
FIG. 13 shows SEQ ID NO.: 6, which is the DNA 
10 sequence from SEQ ID NO.: 1 corresponding to the amino 
acids forming Tier 2. Comparative numbering from Tier 2 
amino acid residues is also shown (SEQ ID NO.: 8). 
FIG. 4 illustrates a sequence alignment of amino acids 
lining the active site (1st tier) and those within 3 A of the 
active site residues (2nd tier) of TEAS with the correspond-
ing positions of CVS. For uniformity, the TEAS amino acids 
numbering was used, and thus the corresponding CVS 
amino acids renumbered-termed comparative numbering. 
The 1st tier residues lie within 3 A of a substrate analog 
co-crystallized within the TEAS enzyme and includes resi-
dues making up the J/K loop which clamps down over the 
active site upon substrate binding. The corresponding resi-
dues within CVS (valencene synthase) were initially iden-
tified by primary sequence alignment, then visual inspection 
of the relevant CVS sequences overlaid on the TEAS 
3-dimensional structure. Residues different from TEAS are 
highlighted. 
FIG. 14a shows the absolute amino acid sequence from 
SEQ ID NO.: 4 corresponding to the Tier 1 amino acid 
15 residues. FIG. 14b shows the comparative amino acid 
sequence of the Tier 1 amino acid residues (SEQ ID NO.: 7) 
FIG. 15a shows the absolute amino acid sequence from 
SEQ ID NO.: 4 corresponding to Tier 2 amino acid residues. 
FIG. 15b shows the comparative amino acid sequence of the 
20 Tier 2 amino acid residues (SEQ ID NO.: 8). 
FIG. 16 is a sequence alignment of the amino acid 
sequence of TEAS active site compared to the amino acid 
sequence of the CVS active site. The alignment maximizes 
residue similarities and introduce gaps where necessary. 
25 Absolute amino acid numbering is shown for CVS, thus 
amino acid numbering from SEQ ID NO.: 4 is shown for 
cvs. 
FIG. 5 shows SEQ ID NO.: 1, which is the DNA sequence 
for the citrus valencene synthase gene from Citrus paradis 30 
isolated in the current invention. 
FIG. 6 shows SEQ ID NO.: 4, which is the protein 
sequence for the citrus valencene synthase from Citrus 
paradisi. 
FIG. 7 illustrates reaction product analysis of citrus val en- 35 
cene synthase (CVS) incubated at pH 7.5. Lysate of E. coli 
expressing the CVS eDNA was incubated with FPP at pH 
7.5 and total pentane extractable products evaluated by 
GC-MS (upper panel). The mass spectrum of the reaction 
product corresponding to peak A (middle panel) is compared 40 
to that of authentic valencene in the lower panel. The mass 
spectrum of peak B is identical to that for beta-elemene, the 
thermal-induced rearrangement product of germacrene A. 
FIG. 8 illustrates a mass spectrum for the peak with a 
retention time of7.38 minutes from FIG. 7 (top) compared 45 
to the spectra for beta-elemene published by the NIST 
library (bottom). 
FIG. 9 illustrates mass spectrum for the peak with a 
retention time of 8.89 in FIG. 7 (top) compared to that for 
valencene purchased from Fluka Chemical Company (bot- 50 
tom). 
FIG. 10 illustrates that the reaction product specificity of 
citrus valencene synthase (CVS) is pH dependent. Partially 
purified synthase isolated from E. coli expressing the CVS 
eDNA was incubated with FPP at the indicated pH values 55 
and ethylacetate extracts were examined directly by GC-
MS. Absolute values for valencene (solid symbols) and 
germacrene A (measured as the thermally rearranged prod-
uct ~-elemene) (open symbols) are reported and represent 
greater than 95% of the total reaction products at all pHs. 60 
FIG. 17 is a chart showing the TEAS Tier 1 and Tier 2 
amino acid residues in column 1; the CVS Tier 1 and Tier 2 
amino acid residues with absolute numbering in colunm 2; 
and the CVS Tier 1 and Tier 2 amino acid residues with 
comparative numbering in colunm 3. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Abbreviations and Terms 
In accordance with the present invention and as used 
herein, the following terms and abbreviations are defined 
with the following meanings, unless explicitly stated other-
wise. These explanations are intended to be exemplary only. 
They are not intended to limit the terms as they are described 
or referred to throughout the specification. Rather, these 
explanations are meant to include any additional aspects 
and/or examples of the terms as described and claimed 
herein. 
The following abbreviations are used herein: 
As used herein, a "derivative" is any compound obtained 
from a known or hypothetical compound and containing 
essential elements of the parent substance. 
The phrase "substantially identical" means that a relevant 
sequence is at least 70%, 75%, 80%, 85%, 90%, 92%, 95% 
96%, 97%, 98%, or 99% identical to a given sequence. By 
way of example, such sequences may be allelic variants, 
sequences derived from various species, or they may be 
derived from the given sequence by truncation, deletion, 
amino acid substitution or addition. Percent identity between 
two sequences is determined by standard alignment algo-
rithms such as ClustalX when the two sequences are in best 
alignment according to the alignment algorithm. FIG. 11 is a sequence aligument of amino acids lining the 
active site (1st tier) of TEAS with the corresponding posi-
tions of HPS and CVS. The 1st tier residues lie within 3 A 
of a substrate analog co-crystallized within the TEAS 
enzyme and includes residues making up the J/K loop which 
clamps down over the active site upon substrate binding. 
The corresponding residues within the other terpene syn-
As used herein, the term "hybridization" or "hybridizes" 
under certain conditions is intended to describe conditions 
for hybridization and washes under which nucleotide 
65 sequences that are significantly identical or homologous to 
each other remain bound to each other. Appropriate hybrid-
ization conditions can be selected by those skilled in the art 
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with minimal experimentation as exemplified in Ausubel, F. 
A.; eta!., eds., Current Protocols in Molecular Biology Vol. 
2, John Wiley and Sons, Inc., New York (1995). Addition-
ally, stringency conditions are described in Sambrook et a!. 
Molecular Cloning: A Laboratory Manual, 2nd ed., Cold 
Spring Harbor Laboratory Press, New York (1989). Varia-
tions on the conditions for low, moderate, and high strin-
gency are well known in the art and may be used with the 
current invention. 
The terms "nucleic acid" or "nucleic acid molecule" refer 
to a deoxyribonucleotide or ribonucleotide polymer in either 
single- or double-stranded form, and unless otherwise lim-
ited, would encompass known analogs of natural nucleotides 
that can function in a similar marmer as naturally occurring 
nucleotides. A "nucleotide sequence" also refers to a poly-
nucleotide molecule or oligonucleotide molecule in the form 
of a separate fragment or as a component of a larger nucleic 
acid. The nucleotide sequence or molecule may also be 
referred to as a "nucleotide probe." Some of the nucleic acid 
molecules of the invention are derived from DNA or RNA 
isolated at least once in substantially pure form and in a 
quantity or concentration enabling identification, manipula-
tion, and recovery of its component nucleotide sequence by 
standard biochemical methods. Examples of such methods, 
including methods for PCR protocols that may be used 
herein, are disclosed in Sambrook et a!. Molecular Cloning: 
A Laboratory Manual, 2nd ed., Cold Spring Harbor Labo-
ratory Press, New York (1989), Ausubel, F. A., eta!., eds., 
Current Protocols in Molecular Biology, John Wiley and 
Sons, Inc., New York (1987), and Innis, M., eta!. (Eds.) PCR 
Protocols: A Guide to Methods and Applications, Academic 
Press, San Diego, Calif. (1990). Reference to a nucleic acid 
molecule also includes its complement as determined by the 
standard Watson-Crick base-pairing rules, with uracil (U) in 
RNA replacing thymine (T) in DNA, unless the complement 
is specifically excluded. 
As described herein, the nucleic acid molecules of the 
invention include DNA in both single-stranded and double-
stranded form, as well as the DNA or RNA complement 
thereof. DNA includes, for example, DNA, genomic DNA, 
chemically synthesized DNA, DNA amplified by PCR, and 
combinations thereof. Genomic DNA, including translated, 
non-translated and control regions, may be isolated by 
conventional techniques, e.g., using any one of the cDNAs 
of the invention, or suitable fragments thereof, as a probe, to 
identify a piece of genomic DNA which can then be cloned 
using methods commonly known in the art. 
8 
restriction nucleotides or codons are altered by substitution, 
deletion or insertion. Exemplary methods of making such 
alterations are disclosed by Walder et a!. (Gene 
42:133.1986); Bauer eta!. (Gene 37:73, 1985); Craik (Bio-
Techniques, Jan. 12-19, 1985); Smith eta!. (Genetic Engi-
neering: Principles and Methods, Plenum Press, 1981); 
Kuukel (Proc. Nat!. Acad. Sci. USA 82:488, 1985); Kuukel 
et a!. (Methods in Enzymol. 154.367, 1987). The present 
invention thus encompasses any nucleic acid capable of 
10 encoding a protein of the current invention. 
The current invention provides for isolated polypeptides. 
As used herein, the term "polypeptides" refers to a genus of 
polypeptide or peptide fragments that encompass the amino 
15 
acid sequences identified herein, as well as smaller frag-
ments. Alternatively, a polypeptide may be defined in terms 
of its antigenic relatedness to any peptide encoded by the 
nucleic acid sequences of the invention. Thus, in one 
embodiment, a polypeptide within the scope of the invention 
20 is defined as an amino acid sequence comprising a linear or 
3-dimensional epitope shared with any peptide encoded by 
the nucleic acid sequences of the invention. Alternatively, a 
polypeptide within the scope of the invention is recognized 
by an antibody that specifically recognizes any peptide 
25 encoded by the nucleic acid sequences of the invention. 
Antibodies are defined to be specifically binding if they bind 
polypeptides of the invention with a Ka of greater than or 
equal to about 107 M-I, such as greater than or equal to 108 
M- 1 . As used herein, the term "isolated," in reference to 
30 polypeptides or proteins, means that the polypeptide or 
protein is substantially removed from polypeptides, pro-
teins, nucleic acids, or other macromolecules with which it, 
or its analogues, occurs in nature. Although the term "iso-
lated" is not intended to require a specific degree of purity, 
35 typically, the protein will be at least about 75% pure, more 
typically at least about 90% pure, preferably at least about 
95% pure, and more preferably at least about 99% pure. 
A polypeptide "variant" as referred to herein means a 
polypeptide substantially homologous to a native polypep-
40 tide, but which has an amino acid sequence different from 
that encoded by any of the nucleic acid sequences of the 
invention because of one or more deletions, insertions or 
substitutions. Variants can comprise conservatively substi-
tuted sequences, meaning that a given amino acid residue is 
45 replaced by a residue having similar physiochemical char-
acteristics. See Zubay, Biochemistry, Addison-Wesley Pub. 
Co., (1983). It is a well-established principle of protein and 
peptide chemistry that certain amino acids substitutions, 
entitled "conservative" amino acid substitutions, can fre-
Polypeptides encoded by the nucleic acids of the inven-
tion are encompassed by the invention. As used herein, 
reference to a nucleic acid "encoding" a protein or polypep-
tide encompasses not only cDNAs and other intronless 
nucleic acids, but also DNAs, such as genomic DNA, with 
introns, on the assumption that the introns included have 
appropriate splice donor and acceptor sites that will ensure 
that the introns are spliced out of the corresponding tran-
script when the transcript is processed in a eukaryotic cell. 
Due to the degeneracy of the genetic code wherein more 
than one codon can encode the same amino acid, multiple 
DNA sequences can code for the same polypeptide. Such 
variant DNA sequences can result from genetic drift or 60 
artificial manipulation (e.g., occurring during PCR amplifi-
cation or as the product of deliberate mutagenesis of a native 
sequence). Deliberate mutagenesis of a native sequence can 
50 quently be made in a protein or a peptide without altering 
either the confirmation or the function of the protein or 
peptide. Such changes include substituting any of isoleucine 
(I), valine (V), and leucine (L) for any other of these amino 
acids; aspartic acid (D) for glutamic acid (E) and vice versa; 
55 glutamine (Q) for asparagine (N) and vice versa; and serine 
(S) for threonine (T) and vice versa. 
The above-mentioned substitutions are not the only amino 
acid substitutions that can be considered "conservative." 
Other substitutions can also be considered conservative, 
depending on the environment of the particular amino acid. 
For example, glycine (G) and alanine (A) can frequently be 
interchangeable, as can be alanine and valine (V). Methio-
nine (M), which is relatively hydrophobic, can frequently be 
interchanged with leucine and isoleucine, and sometimes 
with valine. Lysine (K) and arginine (R) are frequently 
interchangeable in locations in which the significant feature 
be carried out using numerous techniques well known in the 
art. For example, oligonucleotide-directed site-specific 65 
mutagenesis procedures can be employed, particularly 
where it is desired to mutate a gene such that predetermined of the amino acid residue is its charge and the differing pK's 
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of these two amino acid residues are not significant. Still 
other changes can be considered "conservative" in particular 
environments. 
The effects of such substitutions can be calculated using 
substitution score matrices such PAM120, PAM-200, and 
PAM-250 as discussed in Altschul, (J. Mol. Bioi. 219:55565 
(1991)). Other such conservative substitutions, for example, 
substitutions of entire regions having similar hydrophobicity 
characteristics, are well known. 
Naturally-occurring peptide variants are also encom- 10 
passed by the invention. Examples of such variants are 
proteins that result from alternate mRNA splicing events or 
from proteolytic cleavage of the polypeptides described 
herein. Variations attributable to proteolysis include, for 
example, differences in theN- or C-termini upon expression 15 
in different types of host cells, due to proteolytic removal of 
one or more terminal amino acids from the polypeptides 
encoded by the sequences of the invention. 
Variants of the valencene synthase of the invention may 
be used to attain desired enhanced or reduced enzymatic 20 
activity, modified regiochemistry or stereochemistry, or 
altered substrate utilization or product distribution. A variant 
or site direct mutant may be made by any methods known in 
the art. Variants and derivatives of native polypeptides can 
be obtained by isolating naturally-occurring variants, or the 25 
nucleotide sequence of variants, of other or same plant lines 
or species, or by artificially progrming mutations of 
nucleotide sequences coding for native citrus polypeptides. 
10 
producing a polypeptide comprising culturing the host cells 
of the invention under conditions to produce the polypeptide 
is contemplated. In one embodiment the polypeptide is 
recovered. The methods of the invention include methods of 
making at least one valencene synthase of the invention 
comprising culturing a host cell comprising a nucleic acid of 
the invention, and recovering the sesquiterpene synthase 
accnmulated. 
Suitable host cells for expression of polypeptides of the 
invention are well known in the art, and include, but are not 
limited to, prokaryotes, yeast, higher eukaryotic cells, or 
combinations thereof (See for example, Pauwels et a!. 
Cloning Vectors: A Laboratory Manual, Elsevier, New York 
(1985)). Cell-free translation systems, also well known in 
the art, could also be employed to produce the disclosed 
polypeptides using RNAs derived from DNA constructs 
disclosed herein. 
Host cells may be modified by any methods known in the 
art for gene transfer including, for example, the use of 
delivery devices such as lipids and viral vectors, naked 
DNA, electroporation and particle-mediated gene transfer. 
In one embodiment, the cDNAs of the invention may be 
expressed in such a way as to produce either sense or 
antisense RNA. The expression of antisense RNA can be 
used to down-modulate the expression of the protein 
encoded by the mRNA to which the antisense RNA is 
complementary. 
A further embodiment of the invention is methods of In one embodiment, the invention contemplates: vectors 
comprising the nucleic acids of the invention. A vector as 
used herein includes any recombinant vector including but 
not limited to viral vectors, bacteriophages and plasmids. 
30 making terpenoids and sesquiterpene compounds, for 
example, using the nucleotides and polypeptides of the 
Expression vectors containing a nucleic acid sequence of 
the invention can be prepared using well known methods 
and include a eDNA sequence encoding the polypeptide 35 
operably linked to suitable transcriptional or translational 
regulatory nucleotide sequences. Examples of regulatory 
sequences include transcriptional promoters, operators, or 
enhancers, mRNA ribosomal binding sites, and appropriate 
sequences which control transcription and translation initia- 40 
tion and termination. Nucleotide sequences are "operably 
linked" when the regulatory sequence functionally relates to 
the eDNA sequence of the invention. Expression vectors, 
regulatory elements and the construction thereof are well 
known in the art, and therefore are not limited to those 45 
recited above. 
In addition, sequences encoding appropriate signal pep-
tides that are not naturally associated with the polypeptides 
of the invention can be incorporated into expression vectors. 
For example, a DNA sequence for a signal peptide (secre- 50 
tory) leader can be fused in-frame to a nucleotide sequence 
of the invention so that the polypeptide of the invention is 
initially translated as a fusion protein comprising the signal 
peptide. A signal peptide that is functional in the intended 
host cells enhances extracellular secretion of the expressed 55 
polypeptide. The signal peptide can be cleaved from the 
polypeptide upon secretion from the cell. In some cases, 
signal peptides are cleaved in two or more stages; this is also 
within the scope of the invention where appropriate. 
Fusions of additional peptide sequences at the amino and 60 
carboxyl terminal ends of the polypeptides of the invention 
can be used with the current invention. 
In one embodiment, the invention includes a host cell 
comprising a nucleic acid of the invention. Another embodi-
ment of the invention is a method of making a recombinant 65 
host cell comprising introducing the vectors of the inven-
tion, into a host cell. In a further embodiment, a method of 
invention. 
As used herein an acyclic pyrophosphate terpene precur-
sor is any acyclic pryrophosphate compound that is a 
precursor to the production of at least one terpene including 
but not limited to geranyl-pyrophosphate (GPP), farnesyl-
diphosphate (FPP) and geranylgeranyl-pyrophosphate 
(GGPP). 
In one embodiment, the distribution of products or the 
actual products formed may be altered by varying the pH at 
which the synthase contacts the acyclic pyrophosphate ter-
pene precursor. 
Also within the practice of the invention is an organism 
(e.g., microorganism or plant) that is used to construct a 
platform for high level production of a substrate of sesqui-
terpene synthases (e.g., FPP) and the introduction of a 
nucleic acid of the invention into the organism. 
Unless otherwise indicated, nucleic acids of the invention 
that are DNA encompass both eDNA (DNA reverse tran-
scribed from mRNA and lacking introns) and isolated 
genomic DNA (DNA that can contain introns.) 
In one embodiment, the nucleic acids of the invention are 
used to create other nucleic acids coding for sesquiterpene 
synthases. For example, the invention provides for a method 
of identifYing a sesquiterpene synthases comprising con-
structing a DNA library using the nucleic acids of the 
invention, screening the library for nucleic acids which 
encode for at least one sesquiterpene synthase. The DNA 
library using the nucleic acids of the invention may be 
constructed by any process known in the art where DNA 
sequences are created using the nucleic acids of the inven-
tion as a starting point, including but not limited to DNA 
suffling. In such a method, the library may be screened for 
sesquiterpene synthases using a functional assay to find a 
target nucleic acid that encodes a sesquiterpene synthase. 
The activity of a sesquiterpene synthase may be analyzed 
using, for example, the methods described herein. In one 
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embodiment, high through put screening is utilized to ana-
lyze the activity of the encoded polypeptides. 
As used herein a "nucleotide probe" is defined as an 
oligonucleotide or polynucleotide capable of binding to a 
target nucleic acid of complementary sequence through one 
or more types of chemical bonds, through complementary 
base pairing, or through hydrogen bond formation. 
A "target nucleic acid" herein refers to a nucleic acid to 
which the nucleotide probe or molecule can specifically 
hybridize. The probe is designed to determine the presence 
or absence of the target nucleic acid, and the amount of 
target nucleic acid. The target nucleic acid has a sequence 
that is significantly complementary to the nucleic acid 
sequence of the corresponding probe directed to the target so 
that the probe and the target nucleic acid can hybridize. 
Preferably, the hybridization conditions are such that hybrid-
ization of the probe is specific for the target nucleic acid. As 
recognized by one of skill in the art, the probe may also 
contain additional nucleic acids or other moieties, such as 
labels, which may not specifically hybridize to the target. 
The term target nucleic acid may refer to the specific 
nucleotide sequence of a larger nucleic acid to which the 
probe is directed or to the overall sequence (e.g., gene or 
mRNA). One skilled in the art will recognize the full utility 
under various conditions. 
Other than in the operating example, or where otherwise 
indicated, all numbers expressing quantities of ingredients, 
reaction conditions, and so forth used in the specification 
and claims are to be understood as being modified in all 
instances by the term "about." Accordingly, unless indicated 
to the contrary, the numerical parameters set forth in the 
specification and claims are approximations that may vary 
depending upon the desired properties sought to be obtained 
by the present invention. At the very least, and not as an 
attempt to limit the application of the doctrine of equivalents 
to the scope of the claims, each numerical parameter should 
be construed in light of the number of significant digits and 
ordinary rounding approaches. 
Notwithstanding that the numerical ranges and param-
eters setting forth the broad scope of the invention are 
approximations, the numerical values set forth in the specific 
examples are reported as precisely as possible. Any numeri-
cal value; however, inherently contains certain errors nec-
essarily resulting from the standard deviation found in their 
respective testing measurements. 
Hundreds of genes with similarity to terpene synthases are 
readily observed in protein sequence or keyword searches of 
GenBank with a significant percentage of these currently 
annotated as terpene synthase-like. In order to isolate syn-
thase genes coding for enzymes that share catalytic features 
in common with tobacco 5-epi-aristolochene synthase 
(TEAS) or Hyoscyamus muticus prenmaspirodiene synthase 
(HPS) (FIG. 1), Inventors considered possible biosynthetic 
routes for all isomeric forms of the eremophilane-type 
sesquiterpenes (FIG. 2). ( + )Valencene and its oxygenated 
derivative nootkatone (FIG. 3) were readily recognized as 
high value natural products isolated from citrus used as 
flavor enhancers. To identifY the terpene synthase respon-
sible for the biosynthesis of valencene, Inventors screened 
sequences from several citrus (Citrusxparadisi and Citrus 
junos) EST sequencing projects deposited in GenBank (ww-
w.ncbi.nlm.nih.gov/Genbank/index.html) for sequences 
similar to TEAS and HPS. Two sequences were observed, 
one from Citrus junos (accession AF288465) and the other 
from Curtis paradisi (accession AF411120). The predicted 
proteins from both of these cDNAs were between about 40% 
identical and about 60% similar to TEAS, but the C. junos 
12 
eDNA predicted a protein that was missing segments of 10 
and 12 amino acids relative to TEAS. The isolated protein 
from Citrus paradisi was 45% homologous with TEAS (see 
below). Inventors, therefore, focused on the isolation and 
characterization of a full-length eDNA corresponding to 
AF411120 from grapefruit (C. paradisi). 
The eDNA isolated by Inventors is a terpene synthase 
gene, the protein product of which is citrus valencene 
synthase (CVS). The following non-limiting examples 
10 describe Inventors isolation, and expression of the CVS 
gene, and also further characterize the CVS protein via 
enzyme activity assays and pH assays. Applicants have 
further characterized the key amino acid residues compris-
ing the active domain of the CVS protein via these enzyme 
15 activity assays and via a comparison to other eremophilane-
type sesquiterpenes, in particular TEAS, HPS and delta-
cadinene synthase from cotton. 
Sequence comparisons between terpene synthases have 
suggested that simple sequence alignments are not sufficient 
20 to identifY amino acids or protein regions contributing to 
catalytic specificity. Inventors aligned the residues forming 
the active region of the isolated CVS with the residues 
forming active region of TEAS. In order to perform a 
comparative analysis of the two active regions (CVS and 
25 TEAS), the absolute amino acid number for CVS was 
shifted to correspond with the TEAS amino acid numbers. 
FIG. 16 illustrates the alignment ofCVS amino acid residues 
with those of TEAS and maintains the numbering of TEAS 
and the numbering for CVS. Inventors then adjusted the 
30 amino acid numbering of CVS to match that of TEAS 
(comparative numbering). Tier 1 and Tier 2 amino acid 
numbering follows this comparative numbering, thus, Tier 1 
and Tier 2 amino acids would also have the comparative 
numbering shift (SEQ ID NOS.: 7 and 8, respectively). FIG. 
35 17. Thus, as is used herein the term "absolute numbering" 
refers to the sequence number of the CVS amino acid 
residues in SEQ ID NO.: 1 and the nucleotide numbering in 
SEQ ID NO.: 4. As used herein, the term "comparative 
numbering" refers to the sequence numbering of the amino 
40 acid residues based on the TEAS numbering, which were 
designated as a means to compare TEAS and CVS active site 
amino acid residues, and neighboring residues (Tiers 1 and 
2). Nucleic acid residues coding for the amino acids com-
prising Tier 1 (SEQ ID NO.: 5) and Tier 2 (SEQ ID NO.: 6) 
45 are based on the nucleotide sequence of SEQ ID NO.: 1, and 
are absolute numbers. 
As is seen in FIG. 4 and FIG. 11 wherein Inventors 
compared the amino acids of TEAS, HPS and CVS, only a 
single amino acid difference was observed within the 1st tier 
50 residues of TEAS and CVS; however 8 amino acid differ-
ences were observed within the second tier residues of 
TEAS and CVS. CVS exhibits an alanine at position 403 
rather than a threonine as is found in TEAS. Using this 
discovery, Inventors have further compared amino acid 
55 residues surrounding the active site and discovered that 
these amino acids, termed Tier 2 amino acids and discussed 
below, influence the catalytic outcome of these enzymes. 
For clarity in this disclosure, Tier 1 amino acids are the 
amino acid residues that form the catalytic pocket in a 
60 sesquiterpene synthase, and Tier 2 amino acids are those 
amino acids that are within a few angstroms of the Tier 1 
residues, preferably between the range of about 1 angstrom 
and about 5 angstroms, more preferably between the range 
of about 2 angstrom and about 4 angstrom and most pref-
65 erably 3 angstrom. In this disclosure, the amino acid residue 
sequence for Tier 1 and Tier 2, based on the amino acid 
residue sequence of SEQ ID NO.: 4, but adjusted for a 
US 9,534,237 B2 
13 
comparative analysis with TEAS, are SEQ ID NO.: 7, shown 
in FIG. 14b, and SEQ ID NO.: 8, shown in FIG. 15b. The 
corresponding nucleotide sequence for the Tier 1 and Tier 2 
amino acid residues, therefore, are based on the nucleotide 
sequence of SEQ ID NO.: 1, and are SEQ ID NO.: 5, shown 
in FIG. 12, and SEQ ID NO.: 6, shown in FIG. 13. The 
recited amino acid residue sequences, recited position num-
ber, corresponding nucleotide and nucleotide position num-
ber are based on the full protein and nucleotide sequences 
recited in SEQ ID NO. 1 and SEQ ID NO.: 4, respectively. 10 
Because the current invention accounts for frame shift 
14 
Another aspect of the present invention is an isolated 
nucleic acid encoding a protein that has the amino acid 
sequence of SEQ ID NO. 4 with 0 to 20 conservative amino 
acid substitutions, with the proviso that a conservative 
amino acid substitution is not made at amino acids 264, 273, 
403, 404, 440, 444, 520, 527, and 528 in the protein that has 
the amino acid sequence of SEQ ID NO: 4, wherein the 
encoded protein specifically binds farnesyl pyrophosphate in 
a substantially hydrophobic pocket and has sesquiterpene 
synthase activity. Conservative amino acid substitutions are 
defined as above. Preferably, the nucleic acid sequence 
encodes a protein with 0 to 10 conservative amino acid 
substitutions. More preferably, the nucleic acid sequence 
encodes a protein with 0 to 5 conservative amino acid 
mutations, fusion proteins, fragments, degeneracy of the 
genetic code and other events that can change these recited 
sequences and positions without loosing the spirit of the 
current invention, the sequences and positions of these 
events are included in the current invention. 
15 substitutions. Typically, the nucleic acid is DNA. 
Yet another aspect of the present invention is an isolated 
nucleic acid encoding a protein that has the amino acid 
sequence of SEQ ID NO. 4 with 0 to 20 conservative amino 
acid substitutions, with the proviso that a conservative 
Inventors then analyzed the second tier amino acid resi-
dues for the TEAS and CVS protein sequences. Second tier 
residues, those amino acid R groups within a few A of the 
1st tier amino acids, were examined for differences between 
TEAS and CVS (FIG. 4). Three positions within the 2nd tier 
exhibited common differences between TEAS and CVS 
(positions 402, 436 and 516), as well as substitutions unique 
to CVS (270, 401, 407, 448, 515) relative to TEAS. A role 
for 2nd tier residues in catalysis, then, includes determining 
whether a synthase produces a C7 -C8 double bond or a 
C6-C7 double bond. This arises because the final proton 
abstraction occurred at C6 rather than C8, a spatial distance 
20 amino acid substitution is not made at amino acids 20, 264, 
266,270,273,298,302,372,376,401,402,403,404,407, 
436,440,441,444,445,448,512,515,516,519,520,527, 
528, and 529 in the protein that has the amino acid sequence 
of SEQ ID NO: 4, wherein the encoded protein specifically 
25 binds farnesyl pyrophosphate in a substantially hydrophobic 
pocket and has sesquiterpene synthase activity. Preferably, 
the nucleic acid sequence encodes a protein with 0 to 10 
conservative amino acid substitutions. More preferably, the 
nucleic acid sequence encodes a protein with 0 to 5 conser-of 3-4 A or approximately the diameter of a methyl group. 
Equally important, regia-specific abstraction necessarily 
arises from proper geometric positioning of C8 or C6 of the 
eremophylyl cation in proximity to an active site residue or 
activated water molecule capable of the final abstraction. 
Positioning of the final reaction intermediate therefore 
comes about by simple spatial allowances created by the 35 
presence or absence of slightly bulkier R -groups on one side 
30 vative amino acid substitutions. Typically, the nucleic acid is 
DNA. 
of the active site pocket balanced by the converse on the 
opposite site of the pocket. For instance, the poly-threonine 
sequence at positions 401-403 of TEAS is replaced by the 
small amino acids serine, cysteine and alanine in CVS, 40 
which appear balanced by a smaller amino acid (valine 516) 
on the opposite side of the active site pocket in TEAS and 
the larger amino acid isoleucine in CVS. Without being 
bound by any theory, differences between sesquiterpene 
synthases, particularly TEAS and CVS may be due to 45 
alterations of the active site architecture affecting the proton 
donor positioning for proton donation; and/or a dynamic 
mechanism wherein the intermediate compounds are 
brought into proper stereoelectronic aligmnent for the proton 
donation and cyclization geometry. 50 
Yet another aspect of the invention is an isolated nucleic 
acid that hybridizes to the nucleic acid of SEQ ID NO: 1 
under stringent conditions with no more than about a 5% 
mismatch. Preferably, there is no more than about a 2% 
mismatch. More preferably, there is no more than about a 
1% mismatch. Typically, the nucleic acid is DNA. 
Yet another aspect of the invention is an isolated nucleic 
acid that encodes a protein that is at least 500 amino acids 
in length, that specifically binds farnesyl pyrophosphate in a 
hydrophobic pocket, and that has sesquiterpene synthase 
activity, wherein the nucleic acid includes SEQ ID NO. 5 
and SEQ ID NO. 6. Typically, the nucleic acid is DNA. 
Still another aspect of the invention is an isolated nucleic 
acid that encodes a protein that is at least 500 amino acids 
in length, that specifically binds farnesyl pyrophosphate in a 
hydrophobic pocket, and that has sesquiterpene synthase 
activity, wherein the nucleic acid includes SEQ ID NO. 5. 
Typically, the nucleic acid is DNA. 
Still another aspect of the invention is an isolated nucleic 
acid that encodes a protein that includes amino acid residues 
264 to 528 of SEQ ID NO. 4, wherein the protein specifi-
cally binds farnesyl pyrophosphate in a hydrophobic pocket 
and has sesquiterpene synthase activity. Typically, the 
There now follows a description of the isolation, cloning, 
sequencing and functional characterization of citrus valen-
cene synthase from Citrus paradisi. These examples are 
provided for the purpose of illustrating the invention, and are 
not to be considered as limiting. 55 nucleic acid is DNA. 
Accordingly, one aspect of the present invention is an 
isolated nucleic acid comprising the nucleic acid sequence 
of SEQ ID NO 1. The nucleic acid is typically DNA, but can 
be RNA. If it is DNA, it is typically double-stranded, but can 
alternatively be single-stranded. Alternatively, it can be an 60 
RNA-DNA hybrid, i.e., either a complete or partial hybrid. 
Another aspect of the present invention is an isolated 
nucleic acid that encodes the amino acid sequence of SEQ 
ID NO: 4. The nucleic acid is typically DNA, but can be 
RNA. If it is DNA, it is typically double-stranded, but can 65 
alternatively be single-stranded. Alternatively, it can be an 
RNA-DNA hybrid, i.e., either a complete or partial hybrid. 
As defined above, another embodiment of the invention is 
an isolated polypeptide having appropriate enzymatic activ-
ity, namely sesquiterpene synthase activity. These isolated 
polypeptides include, but are not necessary limited to: 
(1) the polypeptide of SEQ ID NO: 4; 
(2) a polypeptide that has the amino acid sequence of SEQ 
ID NO. 4 with 0 to 20 conservative amino acid sub-
stitutions, with the proviso that a conservative amino 
acid substitution is not made at amino acids 264, 273, 
403, 404, 440, 444, 520, 527, and 528 in the protein that 
has the amino acid sequence of SEQ ID NO: 4, wherein 
the encoded protein specifically binds farnesyl pyro-
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phosphate in a substantially hydrophobic pocket and 
has sesquiterpene synthase activity, preferably with 0 to 
10 conservative amino acid substitutions, more prefer-
ably with 0 to 5 conservative amino acid substitutions; 
(3) a polypeptide that has the amino acid sequence of SEQ 
16 
otic host cells for transformation include, for example, E. 
coli, Bacillus subtilis, Salmonella typhimurium, and various 
other species within the genera Pseudomonas, Streptomyces, 
and Staphylococcus. In a prokaryotic host cell, such as E. 
coli, the polypeptides can include aN-terminal methionine 
residue to facilitate expression of the 16 recombinant poly-
peptide in the prokaryotic host cell. TheN-terminal methio-
nine can be cleaved from the expressed recombinant poly-
peptide. 
Examples of useful expression vectors for prokaryotic 
host cells include those derived from commercially available 
plasmids such as the cloning vector pET plasmids (Novagen, 
Madison, Wis., USA) or yet pBR322 (ATCC 37017). 
pBR322 contains genes for ampicillin and tetracycline resis-
ID NO. 4 with 0 to 20 conservative amino acid sub-
stitutions, with the proviso that a conservative amino 
acid substitution is not made at amino acids 20, 264, 
266,270,273,298,302,372,376,401,402,403,404, 
407,436,440,441,444,445,448,512,515,516,519, 10 
520, 527, 528, and 529 in the protein that has the amino 
acid sequence of SEQ ID NO: 4, wherein the encoded 
protein specifically binds farnesyl pyrophosphate in a 
substantially hydrophobic pocket and has sesquiterpene 
synthase activity, preferably with 0 to 10 conservative 
amino acid substitutions, more preferably with 0 to 5 
conservative amino acid substitutions; 
15 tance and thus provides simple means for identifying trans-
formed cells. To construct an expression vector using 
pBR322, an appropriate promoter and a DNA sequence 
encoding one or more of the polypeptides of the invention 
are inserted into the pBR322 vector. Other commercially 
( 4) a polypeptide encoded by an isolated nucleic acid that 
hybridizes to the nucleic acid of SEQ ID NO: 1 under 
stringent conditions with no more than about a 5% 
mismatch, preferably no more than about a 2% mis-
match, more preferably no more than about a 1% 
mismatch; 
(5) a polypeptide that is at least 500 amino acids in length, 
that specifically binds farnesyl pyrophosphate in a 
hydrophobic pocket, and that has sesquiterpene syn-
thase activity, wherein the sequence of the protein 
includes SEQ ID NO. 7 and SEQ ID NO. 8; 
( 6) a polypeptide that is at least 500 amino acids in length, 
that specifically binds farnesyl pyrophosphate in a 
hydrophobic pocket, and that has sesquiterpene syn-
thase activity, wherein the sequence of the protein 
includes SEQ ID NO.7; and 
(7) a polypeptide that includes amino acid residues 264 to 
528 of SEQ ID NO. 4, wherein the protein specifically 
binds farnesyl pyrophosphate in a hydrophobic pocket 
and has sesquiterpene synthase activity. 
Typically, the sesquiterpene synthase activity of proteins 
or polypeptides within the scope of the present invention is 
valencene synthase activity, but other sesquiterpenes can be 
synthesized by proteins or polypeptides within the scope of 
the present invention, either as the major reaction product or 
in side reactions. 
20 available vectors include, for example, pKK223-3 (Pharma-
cia Fine Chemicals, Uppsala, Sweden) and pGEM-1 (Pro-
mega Biotec, Madison, Wis., USA). Other commercially 
available vectors include those that are specifically designed 
for the expression of proteins; these would include pMAL-
25 p2 and pMAL-c2 vectors that are used for the expression of 
proteins fused to maltose binding protein (New England 
Biolabs, Beverly, Mass., USA). 
Promoter sequences commonly used for recombinant 
prokaryotic host cell expression vectors include bacterio-
30 phage T7 promoter (Studier F. W. and Moffatt B. A., J. Mol. 
Bioi. 189:113, 1986), ~-lactamase (penicillinase), lactose 
promoter system (Chang eta!., Nature 275:615, 1978; and 
Goedde! et a!., Nature 281:544, 1979), tryptophan (trp) 
promoter system (Goedde! et a!., Nucl. Acids Res. 8:4057, 
35 19.80; and EP-A-36776), and tac promoter (Maniatis, 
Molecular Cloning: A Laboratory Manual, Cold Spring 
Harbor Laboratory, p. 412. 1982). A particularly useful 
prokaryotic host cell expression system employs a phage A 
PL promoter and a c1857ts thermolabile repressor sequence. 
40 Plasmid vectors available from the American Type Culture 
Collection ("ATCC"), which incorporate derivatives of the 
PL promoter, include plasmid pHUB2 (resident in E. coli 
strain JMB9 (ATCC 37092)) and pPLc28 (resident in E. coli 
Another embodiment of the present invention is a vector 
comprising a nucleic acid of the present invention, as 45 
described above, operably linked to at least one control 
sequence. Typically, the control sequence is a promoter or 
enhancer. As described above, such vectors are well known 
RR1 (ATCC 53082)). 
Polypeptides of the invention can also be expressed in 
yeast host cells, preferably from the Saccharomyces genus 
(e.g., S. cerevisiae). Other genera of yeast, such as Pichia or 
Kluyveromyces (e.g. K. lactis), can also be employed. Yeast 
vectors will often contain an origin of replication sequence in the art. 
Yet another embodiment of the present invention is a host 
cell transformed or transfected with a vector of the present 
invention. The host cell can be a prokaryotic cell or a 
eukaryotic cell, such as a bacterial cell, a yeast cell, a plant 
cell, or an animal cell, such as an insect cell or a mammalian 
cell. Typically, the host cell transformed or transfected with 
the vector is capable of expressing the protein or polypeptide 
encoded by the vector. Suitable host cells for expression of 
polypeptides of the invention include prokaryotes, yeast or 
higher eukaryotic cells. Appropriate cloning and expression 
vectors for use with bacterial, fungal, yeast, and mmalian 
cellular hosts are described, for example, in Pauwels et a!., 
Cloning Vectors. A Laboratory Manual, Elsevier, New York, 
(1985). Cell-free translation systems could also be employed 
to produce the disclosed polypeptides using RNAs derived 
from DNA constructs disclosed herein. 
Prokaryotes include gram negative or grain positive 
organisms, for example, E. coli or Bacilli. Suitable prokary-
50 from a 2fl yeast plasmid, an autonomously replicating 
sequence (ARS), a promoter region, sequences for polyade-
nylation, sequences for transcription termination, and a 
selectable marker gene. Suitable promoter sequences for 
yeast vectors include, among others, promoters for metal-
55 lothionine, 3-phosphoglycerate kinase (Hitzeman et a!., J. 
Bioi. Chern. 255:2073, 1980), or other glycolytic enzymes 
(Hess eta!., J. Adv. Enzyme Reg. 7:149, 1968; and Holland 
eta!., Biochem. 17:4900, 1978), such as enolase, glyceral-
dehyde phosphate dehydrogenase, hexokinase, pyruvate 
60 decarboxylase, phosphofructokinase, glucose phosphate 
isomerase, 3-phosphoglycerate mutase, pyruvate kinase, tri-
osephosphate isomerase, phosphoglucose isomerase, and 
glucokinase. Other suitable vectors and promoters for use in 
yeast expression are further described in Hitzeman, EPA-
65 73,657 or in Fleer et. a!., Gene, 107:285-195 (1991); and van 
den Berget. a!., Bio/Technology, 8:135-139 (1990). Another 
alternative is the glucose-repressible ADH2 promoter 
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described by Russell eta!. (J. Bioi. Chern. 258:2674, 1982) 
and Beier et a!. (Nature 300:724, 1982). Shuttle vectors 
replicable in both yeast and E. coli can be constructed by 
inserting DNA sequences from pBR322 for selection and 
replication in E. coli (Ampr gene and origin of replication) 
into the above-described yeast vectors. 
In one embodiment, mammalian or insect host cell culture 
systems are employed to express recombinant polypeptides 
of the invention. Baculovirus systems for production of 
heterologous proteins in insect cells are reviewed by 10 
Luckow and Surmners, BioTechnology 6:47 (1988). Estab-
lished cell lines of mammalian origin also can be employed. 
Examples of suitable mmalian host cell lines include the 
COS-7 line of monkey kidney cells (ATCC CRL 1651) 
(Gluzman eta!., Cell23:175, 1981), L cells, C1 27 cells, 3T3 15 
cells (ATCC CCL 163), Chinese hamster ovary (CHO) cells, 
HeLa cells, and BHK (ATCC CRL 10) cell lines, and the 
CV-1/EBNA-1 cell line (ATCC CRL 10478) derived from 
the African green monkey kidney cell line CV1 (ATCC CCL 
70) as described by McMahan eta!. (EMBO J. 10: 2821, 20 
1991 ). 
In one embodiment, transfected DNA is integrated into a 
chromosome of a non-human organism such that a stable 
recombinant system results. Any chromosomal integration 
method known in the art may be used in the practice of the 25 
invention, including but not limited to, recombinase-medi-
ated cassette exchange (RMCE), viral site specific chromo-
somal insertion, adenovirus, and pronuclear injection. 
Yet another embodiment of the present invention is a 
non-human multicellular organism that is modified to harbor 30 
a nucleic acid of the present invention such that the nucleic 
acid can be expressed in the non-human multicellular organ-
ism. The non-human multicellular organism can be, but is 
not necessarily limited to, a plant or insect. The plant can be 
the tobacco plant. The non-human organism can be modified 35 
by any of the methods known in the art for gene transfer and 
the production of transgenic organisms, including, but not 
necessarily limited to, the use of delivery devices such as 
lipids and viral vectors, naked DNA, electroporation, and 
particle-mediated gene transfer. 40 
Established methods for introducing DNA into mamma-
lian cells have been described (Kaufman, R. J., Large Scale 
Mammalian Cell Culture, 1990, pp. 15-69). Additional pro-
tocols using commercially available reagents, such as Lipo-
fectamine (Gibco/BRL) or Lipofectamine-Plus, can be used 45 
to transfect cells (Feigner et a!., Proc. Nat!. Acad. Sci. USA 
84:7413-7417, 1987). In addition, electroporation can be 
used to transfect mammalian cells using conventional pro-
cedures, such as those in Sambrook et a!. Molecular Clon-
ing: A Laboratory Manual, 2 ed. Vol. 1-3, Cold Spring 50 
Harbor Laboratory Press, 1989). Selection of stable trans-
formants can be performed using resistance to cytotoxic 
drugs as a selection method. Kaufman et a!., Meth. in 
Enzymology 185:487-511, 1990, describes several selection 
schemes, such as dihydrofolate reductase (DHFR) resis- 55 
tance. A suitable host strain for DHFR selection can be CHO 
strain DX-131 1, which is deficient in DHFR (Urlaub and 
Chasin, Proc. Nat!. Acad. Sci. USA 77:4216-4220, 1980). A 
plasmid expressing the DHFR eDNA can be introduced into 
strain DX-131 1, and only cells that contain the plasmid can 60 
grow in the appropriate selective media. 
Transcriptional and translational control sequences for 
mammalian host cell expression vectors can be excised from 
viral genomes. Commonly used promoter sequences and 
enhancer sequences are derived from polyoma virus, adena- 65 
virus 2, simian virus 40 (SV40), and human cytomegalovi-
rus. DNA sequences derived from the SV40 viral genome, 
18 
for example, SV 40 origin, early and later promoter, 
enhancer, splice, and polyadenylation sites can be used to 
provide other genetic elements for expression of a structural 
gene sequence in a mmalian host cell. Viral early and late 
promoters are particularly useful because both are easily 
obtained from a viral genome as a fragment, which can also 
contain a viral origin of replication (Piers et a!., Nature 
273:113, 1978; Kaufman, Meth. in Enzymology, 1990). 
There are several methods known in the art for the 
creation of transgenic plants. These include, but are not 
limited to: electroporation of plant protoplasts, liposome-
mediated transformation, polyethylene-glycol-mediated 
transformation, microinjection of plant cells, and transfor-
mation using viruses. In one embodiment, direct gene trans-
fer by particle bombardment is utilized. 
Direct gene transfer by particle bombardment provides an 
example for transforming plant tissue. In this technique a 
particle, or microprojectile, coated with DNA is shot through 
the physical barriers of the cell. Particle bombardment can 
be used to introduce DNA into any target tissue that is 
penetrable by DNA coated particles, but for stable transfor-
mation, it is imperative that regenerable cells be used. 
Typically, the particles are made of gold or tungsten. The 
particles are coated with DNA using either CaCI2 or ethanol 
precipitation methods which are commonly known in the 
art. 
DNA coated particles are shot out of a particle gun. A 
suitable particle gun can be purchased from Bio-Rad Labo-
ratories (Hercules, Calif.). Particle penetration is controlled 
by varying parameters such as the intensity of the explosive 
burst, the size of the particles, or the distance particles must 
travel to reach the target tissue. 
The DNA used for coating the particles may comprise an 
expression cassette suitable for driving the expression of the 
gene of interest that will comprise a promoter operably 
linked to the gene of interest. 
Methods for performing direct gene transfer by particle 
bombardment are disclosed in U.S. Pat. No. 5,990,387 to 
Tomes et a!., incorporated herein by this reference. 
In one embodiment, the cDNAs of the invention may be 
expressed in such a way as to produce either sense or 
antisense RNA. Antisense RNA is RNA that has a sequence 
which is the reverse complement of the mRNA (sense RNA) 
encoded by a gene. A vector that will drive the expression of 
antisense RNA is one in which the ONA is placed in "reverse 
orientation" with respect to the promoter such that the 
non-coding strand (rather than the coding strand) is tran-
scribed. The expression of antisense RNA can be used to 
down-modulate the expression of the protein encoded by the 
mRNA to which the antisense RNA is complementary. 
Vectors producing antisense RNAs could be used to make 
transgenic plants, as described above. 
In one embodiment, transfected DNA is integrated into a 
chromosome of a non-human organism such that a stable 
recombinant systems results. Any chromosomal integration 
method known in the art may be used in the practice of the 
invention, including but not limited to, recombinase-medi-
ated cassette exchange (RMCE), viral site specific chromo-
somal insertion, adenovirus, and pronuclear injection. 
Still another embodiment of the invention is a method of 
producing a sesquiterpene synthase comprising the steps of: 
(1) culturing a host cell transformed or transfected by a 
vector of the present invention under conditions in 
which the sesquiterpene synthase encoded by the vector 
is expressed; and 
(2) isolating the sesquiterpene synthase expressed by the 
host cell. 
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Typically, the sesquiterpene synthase is valencene syn-
thase, as described above. 
Yet another embodiment of the invention is a method of 
producing a sesquiterpene comprising the steps of: 
20 
an aliquot of the first strand eDNA using standard PCR 
conditions. An amplification fragment approximating the 
expected size of 1,800 bp was observed by agarose gel 
(1) reacting a protein or polypeptide of the present inven- 5 
tion having sesquiterpene synthase enzymatic activity 
with famesyl pyrophosphate under conditions in which 
the enzymatic activity catalyzes the formation of a 
sesquiterpene; and 
electrophoresis, T/A cloned into the pGem T-easy vector 
(Promega, Madison, Wis.) and then subjected to automated 
DNA sequencing using the BigDye terminator system with 
an ABI 310 sequencer. The sequence, which is shown in 
FIG. 5, was obtained from start to stop codons in duplicate 
and rectified with the reported sequence for the Citrusx 
(2) isolating the sesquiterpene formed in step (1). 
Typically, the sesquiterpene synthase is a valencene syn-
thase, in which case the sesquiterpene formed is valencene. 
Still another embodiment of the present invention is a 
method of producing nootkatone. In one alternative of this 
embodiment, the method comprises the steps of: 
(1) reacting a protein or polypeptide of the present inven-
tion having valencene synthase enzymatic activity with 
famesyl pyrophosphate under conditions in which the 
enzymatic activity catalyzes the formation of valen-
cene; 
(2) reacting the valencene formed in step (1) by regia-
specific hydroxylation and then oxidation to form noot-
katone; and 
(3) isolating the nootkatone produced. 
10 paradisi putative terpene synthase mRNA. (Seq ID: 1). One 
nucleotide was found to be altered in the recovered eDNA, 
1544 bp 5' to the ATG start site an A instead of a G was 
observed, converting codon 492 from specifYing an aspar-
tate to an arginine. Sequence analysis was performed using 
15 software tools available from the NCBI web site (ww-
w.ncbi.nlm.nih.gov) or using ClustalX. 
Example 2 
20 Expression of Citrus Valencene Synthase in E. coli 
The Citrus valencene synthase (CVS) eDNA was inserted 
The second step could be catalyzed by a single multi- 25 
functional hydroxylase or could be catalyzed by sequential 
enzyme mediated reactions. 
into an appropriate expression vector, pGEM to provide an 
amino-terminal hexa-histidyl tag for protein purification 
after expression of the putative valencene synthase eDNA in 
E. coli. The eDNA was re-amplified using PCR primers 
designed to amplify from the ATG start codon (5'-
GGGGAATTCATCTGGTCTGGAGAAACATTTCGTCC-
3' (SEQ ID NO.: 2) to the TGA stop codon (5'-CCGCTC-
Yet another embodiment of the invention is an antisense 
nucleic acid that is the complement of a nucleic acid 
according to the present invention as described above. 
EXAMPLES 
30 GAGGAAGTATAGAACTAGTCGTCAAAATGG-3' (SEQ 
ID N0.:3)) and to provide restriction sites EcoRI and Xhoi, 
(NEB, Beverly Mass.) respectively, using the pGEM-CVS 
plasmid as template under standard PCR conditions. The 
A eDNA of 1710 bp was prepared from fresh grapefruit 
via RT-PCR using non-degenerate primers designed to 35 
amplify from the translation stall to, stop sites of AF411120, 
then inserted into appropriate vectors for DNA sequencing 
and bacterial expression. For enzymological studies, the 
eDNA was inserted into a pET expression vector in-frame 
with an amino terminal hexa-histidine tag, and lysates of 40 
appropriately grown bacterial cultures used for nickel-affin-
PCR product was digested with EcoRI and Xhoi, purified 
using a QIAquick PCR purification kit (Qiagen, Valencia, 
Calif.), and ligated into a pET-28a( +) expression vector 
(Novagen, San Diego, Calif.) that had been digested with 
corresponding enzymes (NEB, Beverly Mass.), dephospho-
rylated with calf intestine alkaline phosphatase (Invitrogen, 
Carlsbad, Calif.), and purified with a QIAquick kit. Proper 
construction of the resulting expression vector was verified 
ity purification of the citrus eDNA encoded protein. The 
isolated citrus protein was approximately 30-40% pure as 
determined by Coomassie blue staining after SDS-PAGE 
and migrated as a 64 kD polypeptide (data not shown). The 45 
conceptual translation of the isolated eDNA predicted a 
protein of 548 amino acids having a molecular size of 
63,646 daltons. 
by DNA sequencing and subsequently referred to as the 
pET-28a( + )-CVS expression vector. The expression vector 
was transformed into BL21 (DE3) cells (Stratagene, La 
Jolla, Calif.), and grown in a 10 mL inoculate ofLB Growth 
Media, using well known techniques. The cells were grown 
to an OD600=1. IPTG (Sigma-Aldrich, St. Louis, Mo.) was 
used to induce expression of the putative valencene synthase 
gene. The transformed cells were incubated at 28° C. for 
Example 1 
Molecular Cloning of a Citrus Sesquiterpene 
Synthase eDNA 
RNA was isolated from the juice vesicles of freshly 
harvested red grapefruit using TRIZOL reagent and follow-
ing the manufacturer's protocol (Invitrogen Corp., Carlsbad, 
Calif.). Reverse transcription of the isolated RNA also 
followed manufacturer's protocol, and 10 flg of total RNA 
was reverse transcribed using Superscript II RNase H 
(Strata gene, La Jolla Calif.) and a reverse primer (18 nucleo-
tides in length) complementary to the 3' end including the 
stop codon of the AF 411120 sequence reported in Genbank. 
A full-length eDNA was then amplified using Pfu turbo Taq 
polymerase (Stratagene, La Jolla Calif.), more of the initial 
reverse primer, a forward primer (18 nucleotides in length) 
complementary to the 5' end initiating at the start codon, and 
50 four hours, centrifuged to form a pellet and the pellet was 
collected and resuspended in 1 mL of cyclase buffer (200 
mM Tris-HCl, pH 7.5, 40 mM MgC12 ). Cells were then 
sonicated with three 10-sec bursts using a microtip ultra-
sonicator at 40% power and the lysate was centrifuged at 
55 10,000xg for 10 minutes. 
Samples of the lysate were divided and some samples 
were assayed for protein purity, while other samples were 
used in Example 3 below. For the protein purity assay, 
protein was purified by nickel affinity chromatography 
60 according to Mathis et a!. (J. R. Mathis, K. Back, C. Starks, 
J. Noel, C. D. Poulter, J. Chappell, Biochem. 36 (1997) 
8340-8348). Isolated CVS protein was approximately 30 to 
40% pure based on the intensity of Coomassie blue staining 
of samples analyzed by SDS-PAGE. A protein sequencing 
65 reaction was performed via the Edman Degradation reaction 
performed using a Perkin Elmer Applied Biosystems Model 
494 Procise protein/peptide sequencer with an on-line Per-
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kin Elmer Applied Biosystems Model 140C PTH Amino 
Acid Analyzer. The protein sequence for the expressed CVS 
protein is shown in FIG. 6. (SEQ ID NO.; 4) 
Partially purified protein was subsequently incubated with 
FPP at pH 7.5 using typical sesquiterpene synthase reaction 
conditions and the pentane extractable products examined 
22 
accumulate in citrus fruit suggested that the CVS enzyme 
might have a pH optimal different from other terpene 
synthases. 
by GC-MS (FIG. 7). Two compounds accounting for greater 
than 95% of the total reaction products dominated the GC 
profiles and were identified as beta-elemene (30%) and 
valencene (65%) on the basis ofMS matches with authentic 10 
standards. The beta-elemene peak most certainly represents 
As shown in FIG. 10, virtually no germacrene A was 
detected as a reaction product between pH 6.0 to 7.0, with 
optimal valencene biosynthesis occurring at pH 7.0 (FIG. 
10). In contrast, germacrene A biosynthesis was optimal at 
pH 8.5 with a relatively sharp transition point from valence 
as the dominate reaction product to germacrene A at pH 8.0. 
Example 4 
a thermal rearrangement product of germacrene A resulting 
from high temperature injection into the GC. 
Example 3 
Terpene Synthase Activity Assays and Reaction 
Product Identification 
Small scale reactions of 50 f.LL were used for screening 
purposes and rate determinations. Reactions typically con-
tained 200 mM Tris-HCl, pH 7.5, 40 mM MgC12 , 0.5 fJ.Ci 
[1-3H]FPP, 25-30 f.LM FPP and 160 nM enzyme. For kinetic 
determinations, 10 f.LL aliquots of FPP (giving final concen-
trations of 0.7-23 f.LM) were rapidly mixed with 40 f.LL of 
enzyme solution at room temperature (23° C.) and allowed 
to incubate for 1 minute. The reactions were terminated by 
addition of 150 f.LL, of a 100 mM KOH, 0.5 M EDTA stop 
solution. Reactions were extracted with 500 f.LL of hexane 
and an aliquot was taken for determination of radiolabeled 
hydrophobic product via liquid scintillation counting. 
Hexane extracted samples were not subject to silica chro-
matography prior to counting because background was 
minimal and synthase mutants could possibly produce reac-
tion products containing alcohols, which would bind to 
silica. Kinetic constants were determined from direct fits of 
the Michaelis-Menton equation to the data using Graphpad 
Prism 2.01 software. 
Initial synthase reaction products were examined by GC-
MS. Preparative reactions were performed similarly to the 
reactions described above except they were scaled to 2.5 mL 
and employed 2 f.LM of purified enzyme and 80 f.LM of 
unlabeled FPP. The reactions were incubated for 1 hr and 
then extracted twice with 2 mL of pentane. Pooled extracts 
were dried to 50 f.LL under a stream of nitrogen gas and 1 f.LL 
aliquots of this organic extract were analyzed by GC-MS 
using an HP-GCDplus (Hewlett-Packard, Palo Alto, Calif.) 
equipped with a DB-5 ms colunm, an injector temperature of 
250° C. and the mass selective detector set to scan for ions 
within the range from 45 to 250 m/z. The GC was pro-
grammed to hold for 1 minute at 100° C., followed by a 
temperature ramp of8° C./min to a final temperature of270° 
C. The results are shown in FIG. 7. Spectra from this 
analysis was compared to the NIST library standard for 
beta-elemene (FIG. 8) and to that for a sample ofvalencene 
purchased from Fluka Chemical Company (FIG. 9). 
The dominance of valencene as a reaction product under 
these conditions was sufficient to classify the C. paradisi 
eDNA as citrus valencene synthase, CVS. However, the 
amount of germacrene A, a putative reaction intermediate 
(FIG. 1), generated by the CVS enzyme was atypical relative 
to previous studies with TEAS and HPS. Neither of these 
enzymes release appreciable amounts of reaction interme-
diates. Further consideration of the acidic conditions likely 
to exist within juice vesicles/sacs where sesquiterpenes 
pH Dependence Assays 
15 Reactions to determine pH dependence were performed in 
glass GC-vials with 100 nM of purified enzyme, 20 mM 
MgC12 , 50 f.LM FPP (Echelon; Salt Lake City, Utah), and 100 
mM buffer at various pH values; total reaction volume 500 
f.LL. The buffers were chosen within one pH unit of the 
20 buffer's pKa (pH 5-5.5, acetate; pH 6-7, MES; pH 7.5-9, 
Tris; pH 9.5-10, ethanolamine; pH 10.5, CAPS). Reactions 
were allowed to proceed at room temperature for 30 min 
prior to overlaying with 500 f.LL of ethylacetate, vortexing for 
10 sec, then direct analysis of the reaction products using an 
25 HP 6890 gas chromatograph with a 5973 mass spectrometer 
(Agilent Technologies, Palo Alto, Calif.) with an auto-
sampler programmed to remove 1 samples only from the 
organic phase. GC separations were performed on a 5%-phe-
nyl-methylpolysiloxane colunm (J&M Scientific, Folsom, 
30 Calif.) of 30 mx0.25 mm i.d.x0.25 m thickness with He as 
the carrier gas at 2 mL/min and a temperature gradient of 1 oo 
C./min from 50° C. (5-min hold) to 180° C. (4-min hold). 
GC/MS data was analyzed using HP-Chemstation software 
(version B.01.00) and integration of terpene peaks used for 
35 quantification. 
As seen in FIG. 10, a pH dependent transition between 
valencene and germacrene A biosynthesis occurs at approxi-
mately pH 8.2. Inventors interpreted this as a titration point 
for the protonation of germacrene A. This pH value is close 
40 to the pKa value of 8.3-8.5 for free cysteine, which is 
involved in the second protonation step of the chemical 
cascade catalyzed by TEAS. Those results demonstrated that 
when C440 of TEAS was mutated to alanine, a robust 
germacrene A synthetic activity resulted. In combination 
45 with the sequence data provided in SEQ ID NO.: 7 and SEQ 
ID NO.: 8, it is apparent that germacrene synthases consis-
tently differ from CVS, TEAS and HPS by the absence of 
cysteine at position 440 in their putative active site while 
Y520, previously implicated in the same protonation step, is 
50 conserved. The observation of germacrene A as a reaction 
product and the pH dependence for its synthesis are consis-
tent with its intermediacy in the reaction catalyzed by CVS. 
The inventions illustratively described herein can suitably 
be practiced in the absence of any element or elements, 
55 limitation or limitations, not specifically disclosed herein. 
Thus, for example, the terms "comprising," "including," 
"containing," etc. shall be read expansively and without 
limitation. Additionally, the terms and expressions 
employed herein have been used as terms of description and 
60 not of limitation, and there is no intention in the use of such 
terms and expressions of excluding any equivalents of the 
future shown and described or any portion thereof, and it is 
recognized that various modifications are possible within the 
scope of the invention claimed. Thus, it should be under-
65 stood that although the present invention has been specifi-
cally disclosed by preferred embodiments and optional 
features, modification and variation of the inventions herein 
US 9,534,237 B2 
23 24 
disclosed can be resorted by those skilled in the art, and that 
such modifications and variations are considered to be 
within the scope of the inventions disclosed herein. The 
inventions have been described broadly and generically 
herein. Each of the narrower species and sub generic group-
ings falling within the scope of the generic disclosure also 
form part of these inventions. This includes the generic 
description of each invention with a proviso or negative 
limitation removing any subject matter from the genus, 
regardless of whether or not the excised materials specifi- 10 
cally resided therein. 
In addition, where features or aspects of an invention are 
described in terms of the Markush group, those schooled in 
the art will recognize that the invention is also thereby 
described in terms of any individual member or subgroup of 
members of the Markush group. It is also to be understood 
that the above description is intended to be illustrative and 
not restrictive. Many embodiments will be apparent to those 
of in the art upon reviewing the above description. The scope 
of the invention should therefore, be determined not with 
reference to the above description, but should instead be 
determined with reference to the appended claims, along 
with the full scope of equivalents to which such claims are 
entitled. The disclosures of all articles and references, 
including patent publications, are incorporated herein by 
reference. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 8 
<210> SEQ ID NO 1 
<211> LENGTH, 1647 
<212> TYPE, DNA 
<213> ORGANISM, Citrus X paradisi 
<400> SEQUENCE, 1 
atgtcgtctg gagaaacatt tcgtcctact gcagatttcc atcctagttt atggagaaac 60 
catttcctca aaggtgcttc tgatttcaag acagttgatc atactgcaac tcaagaacga 120 
cacgaggcac tgaaagaaga ggtaaggaga atgataacag atgctgaaga taagcctgtt 180 
cagaagttac gcttgattga tgaagtacaa cgcctggggg tggcttatca ctttgagaaa 240 
gaaatagaag atgcaatact aaaattatgt ccaatctata ttgacagtaa tagagctgat 300 
ctccacaccg tttcccttca ttttcgattg cttaggcagc aaggaatcaa gatttcatgt 360 
gatgtgtttg agaagttcaa agatgatgag ggtagattca agtcatcgtt gataaacgat 420 
gttcaaggga tgttaagttt gtacgaggca gcatacatgg cagttcgcgg agaacatata 480 
ttagatgaag ccattgcttt cactaccact cacctgaagt cattggtagc tcaggatcat 540 
gtaaccccta agcttgcgga acagataaat catgctttat accgtcctct tcgtaaaacc 600 
ctaccaagat tagaggcgag gtattttatg tccatgatca attcaacaag tgatcattta 660 
tacaataaaa ctctgctgaa ttttgcaaag ttagatttta acatattgct agagccgcac 720 
aaggaggaac tcaatgaatt aacaaagtgg tggaaagatt tagacttcac tacaaaacta 780 
ccttatgcaa gagacagatt agtggagtta tatttttggg atttagggac atacttcgag 840 
cctcaatatg catttgggag aaagataatg acccaattaa attacatatt atccatcata 900 
gatgatactt atgatgcgta tggtacactt gaagaactca gcctctttac tgaagcagtt 960 
caaagatgga atattgaggc cgtagatatg cttccagaat acatgaaatt gatttacagg 1020 
acactcttag atgcttttaa tgaaattgag gaagatatgg ccaagcaagg aagatcacac 1080 
tgcgtacgtt atgcaaaaga ggagaatcaa aaagtaattg gagcatactc tgttcaagcc 1140 
aaatggttca gtgaaggtta cgttccaaca attgaggagt atatgcctat tgcactaaca 1200 
agttgtgctt acacattcgt cataacaaat tccttccttg gcatgggtga ttttgcaact 1260 
aaagaggttt ttgaatggat ctccaataac cctaaggttg taaaagcagc atcagttatc 1320 
tgcagactca tggatgacat gcaaggtcat gagtttgagc agaagagagg acatgttgcg 1380 
tcagctattg aatgttacac gaagcagcat ggtgtctcta aggaagaggc aattaaaatg 1440 
tttgaagaag aagttgcaaa tgcatggaaa gatattaacg aggagttgat gatgaagcca 1500 
accgtcgttg cccgaccact gctcgggacg attcttaatc ttgctcgtgc aattgatttt 1560 
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-continued 
atttacaaag aggacgacgg ctatacgcat tcttacctaa ttaaagatca aattgcttct 
gtgctaggag accacgttcc attttga 
<210> SEQ ID NO 2 
<211> LENGTH, 35 
<212> TYPE, DNA 
<213> ORGANISM, Citrus X paradisi 
<400> SEQUENCE, 2 
ggggaattca tctggtctgg agaaacattt cgtcc 
<210> SEQ ID NO 3 
<211> LENGTH, 36 
<212> TYPE, DNA 
<213> ORGANISM, Citrus X paradisi 
<400> SEQUENCE, 3 
ccgctcgagg aagtatagaa ctagtcgtca aaatgg 
<210> SEQ ID NO 4 
<211> LENGTH, 548 
<212> TYPE, PRT 
<213> ORGANISM, Citrus X paradisi 
<400> SEQUENCE, 4 
Met Ser Ser Gly Glu Thr Phe Arg Pro Thr Ala Asp Phe His Pro Ser 
1 5 10 15 
Leu Trp Arg Asn His Phe Leu Lys Gly Ala Ser Asp Phe Lys Thr Val 
20 25 30 
Asp His Thr Ala Thr Gln Glu Arg His Glu Ala Leu Lys Glu Glu Val 
35 40 45 
Arg Arg Met Ile Thr Asp Ala Glu Asp Lys Pro Val Gln Lys Leu Arg 
50 55 60 
Leu Ile Asp Glu Val Gln Arg Leu Gly Val Ala Tyr His Phe Glu Lys 
65 70 75 80 
Glu Ile Glu Asp Ala Ile Leu Lys Leu Cys Pro Ile Tyr Ile Asp Ser 
85 90 95 
Asn Arg Ala Asp Leu His Thr Val Ser Leu His Phe Arg Leu Leu Arg 
100 105 110 
Gln Gln Gly Ile Lys Ile Ser Cys Asp Val Phe Glu Lys Phe Lys Asp 
115 120 125 
Asp Glu Gly Arg Phe Lys Ser Ser Leu Ile Asn Asp Val Gln Gly Met 
130 135 140 
Leu Ser Leu Tyr Glu Ala Ala Tyr Met Ala Val Arg Gly Glu His Ile 
145 150 155 160 
Leu Asp Glu Ala Ile Ala Phe Thr Thr Thr His Leu Lys Ser Leu Val 
165 170 175 
Ala Gln Asp His Val Thr Pro Lys Leu Ala Glu Gln Ile Asn His Ala 
180 185 190 
Leu Tyr Arg Pro Leu Arg Lys Thr Leu Pro Arg Leu Glu Ala Arg Tyr 
195 200 205 
Phe Met Ser Met Ile Asn Ser Thr Ser Asp His Leu Tyr Asn Lys Thr 
210 215 220 
Leu Leu Asn Phe Ala Lys Leu Asp Phe Asn Ile Leu Leu Glu Pro His 
225 230 235 240 
Lys Glu Glu Leu Asn Glu Leu Thr Lys Trp Trp Lys Asp Leu Asp Phe 
245 250 255 
26 
1620 
1647 
35 
36 
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Thr Thr Lys Leu Pro Tyr Ala Arg Asp Arg Leu Val Glu Leu Tyr Phe 
260 265 270 
Trp Asp Leu Gly Thr Tyr Phe Glu Pro Gln Tyr Ala Phe Gly Arg Lys 
275 280 285 
Ile Met Thr Gln Leu Asn Tyr Ile Leu Ser Ile Ile Asp Asp Thr Tyr 
290 295 300 
Asp Ala Tyr Gly Thr Leu Glu Glu Leu Ser Leu Phe Thr Glu Ala Val 
305 310 315 320 
Gln Arg Trp Asn Ile Glu Ala Val Asp Met Leu Pro Glu Tyr Met Lys 
325 330 335 
Leu Ile Tyr Arg Thr Leu Leu Asp Ala Phe Asn Glu Ile Glu Glu Asp 
340 345 350 
Met Ala Lys Gln Gly Arg Ser His Cys Val Arg Tyr Ala Lys Glu Glu 
355 360 365 
Asn Gln Lys Val Ile Gly Ala Tyr Ser Val Gln Ala Lys Trp Phe Ser 
370 375 380 
Glu Gly Tyr Val Pro Thr Ile Glu Glu Tyr Met Pro Ile Ala Leu Thr 
385 390 395 400 
Ser Cys Ala Tyr Thr Phe Val Ile Thr Asn Ser Phe Leu Gly Met Gly 
405 410 415 
Asp Phe Ala Thr Lys Glu Val Phe Glu Trp Ile Ser Asn Asn Pro Lys 
420 425 430 
Val Val Lys Ala Ala Ser Val Ile Cys Arg Leu Met Asp Asp Met Gln 
435 440 445 
Gly His Glu Phe Glu Gln Lys Arg Gly His Val Ala Ser Ala Ile Glu 
450 455 460 
Cys Tyr Thr Lys Gln His Gly Val Ser Lys Glu Glu Ala Ile Lys Met 
465 470 475 480 
Phe Glu Glu Glu Val Ala Asn Ala Trp Lys Asp Ile Asn Glu Glu Leu 
485 490 495 
Met Met Lys Pro Thr Val Val Ala Arg Pro Leu Leu Gly Thr Ile Leu 
500 505 510 
Asn Leu Ala Arg Ala Ile Asp Phe Ile Tyr Lys Glu Asp Asp Gly Tyr 
515 520 525 
Thr His Ser Tyr Leu Ile Lys Asp Gln Ile Ala Ser Val Leu Gly Asp 
530 535 540 
His Val Pro Phe 
545 
<210> SEQ ID NO 5 
<211> LENGTH, 1647 
<212> TYPE, DNA 
<213> ORGANISM, Citrus X paradisi 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (789) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (793) .. (816) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (820) .. (1206) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1213) .. (1320) 
<223> OTHER INFORMATION, n is a, c, g, or t 
28 
29 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1324) .. (1332) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1336) .. (1563) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1567) .. (1575) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1579) .. (1581) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1588) .. (1647) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<400> SEQUENCE, 5 
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nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnna gannnnnnnn nnnnnnnnnn nnnnnntggn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnngctt acnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
tgcnnnnnnn nngatnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnntacnnnn nnnnngacnn ntatacgnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnn 
30 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1560 
1620 
1647 
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<210> SEQ ID NO 6 
<211> LENGTH, 1647 
<212> TYPE, DNA 
<213> ORGANISM, Citrus X paradisi 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (36) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (40) .. (795) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (799) .. (807) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (811) .. (891) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (895) .. (903) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (907) .. (1113) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1117) .. (1125) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1129) .. (1200) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1207) .. (1218) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1222) .. (1308) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1312) .. (1323) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1327) .. (1335) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1339) .. (1344) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1348) .. (1539) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1543) .. (1548) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1555) .. ( 1560) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1564) .. (1587) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1591) .. ( 1647) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<400> SEQUENCE, 
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nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnttcn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnagann nnnnnnntta nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn ntccnnnnnn 
nnngatnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnngtannnn nnnnntacnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
agttgtnnnn nnnnnnnngt cnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnngc annnnnnnnn 
nnnagannnn nnnnngacnn nnnnggtnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnc ttnnnnnngc aattnnnnnn 
attnnnnnnn nnnnnnnnnn nnnnnnncat nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnn 
<210> SEQ ID NO 7 
<211> LENGTH, 548 
<212> TYPE, PRT 
<213> ORGANISM, Citrus X paradisi 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (263) 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1560 
1620 
1647 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (265) .. (272) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (274) .. (402) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (405) .. (440) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
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<221> NAME/KEY, misc_feature 
<222> LOCATION, (442) .. (444) 
-continued 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (446) .. (521) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (523) .. (525) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (527) .. (527) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (530) .. (548) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<400> SEQUENCE, 7 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1 5 10 15 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
20 25 30 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
35 40 45 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
50 55 60 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
65 70 75 80 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
85 90 95 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
100 105 110 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
115 120 125 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
130 135 140 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
145 150 155 160 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
165 170 175 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
180 185 190 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
195 200 205 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
210 215 220 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
225 230 235 240 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
245 250 255 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
260 265 270 
Trp Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
275 280 285 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
290 295 300 
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-continued 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
305 310 315 320 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
325 330 335 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
340 345 350 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
355 360 365 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
370 375 380 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
385 390 395 400 
Xaa Xaa Ala Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
405 410 415 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
420 425 430 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Asp Xaa Xaa Xaa 
435 440 445 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
450 455 460 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
465 470 475 480 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
485 490 495 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
500 505 510 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Xaa Xaa Xaa Asp Xaa Tyr 
515 520 525 
Thr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
530 535 540 
Xaa Xaa Xaa Xaa 
545 
<210> SEQ ID NO 8 
<211> LENGTH, 548 
<212> TYPE, PRT 
<213> ORGANISM, Citrus X paradisi 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (12) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (14) .. (265) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (267) .. (269) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (271) .. (297) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (299) .. (301) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (303) .. (371) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
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-continued 
<222> LOCATION, (373) .. (375) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (377) .. (400) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (403) .. (406) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (408) .. (436) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (438) .. (441) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (443) .. (445) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (447) .. (448) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (450) .. (513) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (515) .. (516) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (519) .. (520) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (522) .. (529) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (531) .. (548) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<400> SEQUENCE, 8 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa 
1 5 10 15 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
20 25 30 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
35 40 45 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
50 55 60 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
65 70 75 80 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
85 90 95 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
100 105 110 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
115 120 125 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
130 135 140 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
145 150 155 160 
40 
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-continued 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
165 170 175 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
180 185 190 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
195 200 205 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
210 215 220 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
225 230 235 240 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
245 250 255 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Xaa Xaa Xaa Leu Xaa Xaa 
260 265 270 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
275 280 285 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Xaa Xaa Xaa Asp Xaa Xaa 
290 295 300 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
305 310 315 320 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
325 330 335 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
340 345 350 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
355 360 365 
Xaa Xaa Xaa Val Xaa Xaa Xaa Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
370 375 380 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
385 390 395 400 
Ser Cys Xaa Xaa Xaa Xaa Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
405 410 415 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
420 425 430 
Xaa Xaa Xaa Xaa Ala Xaa Xaa Xaa Xaa Arg Xaa Xaa Xaa Asp Xaa Xaa 
435 440 445 
Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
450 455 460 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
465 470 475 480 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
485 490 495 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
500 505 510 
Xaa Leu Xaa Xaa Ala Ile Xaa Xaa Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
515 520 525 
Xaa His Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
530 
Xaa Xaa Xaa Xaa 
545 
535 540 
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We claim: 
1. A host cell, comprising a recombinant nucleic acid 
encoding a valencene synthase, 
wherein the nucleic acid encoding the valencene synthase 
polypeptide is heterologous to the host cell; 
wherein the valencene synthase polypeptide comprises a 
sequence of amino acid residues that has at least 90% 
sequence identity to SEQ ID N0:4; 
and wherein the host cell produces valencene. 
2. The host cell of claim 1, wherein the host cell is a yeast 10 
cell, a bacterial cell, an insect cell, or a plant cell. 
3. The host cell of claim 1, wherein the nucleic acid is a 
vector. 
4. The host cell of claim 3, wherein the vector is a viral 
vector, bacteriophage, or a plasmid. 15 
5. A method of producing valencene, comprising: 
(a) growing the host cell of any one of claim 1, 2, 3, or 4 
under conditions in which the nucleic acid encoding the 
valencene synthase polypeptide is expressed; and 
(b) isolating the valencene produced by the host cell. 20 
6. The method of claim 5, further comprising reacting the 
valencene by a regiospecific hydroxylation and oxidation to 
produce nootkatone. 
7. The method of claim 5, wherein the regiospecific 
hydroxylation and oxidation are catalyzed by a single mul- 25 
tifunctional hydroxylase. 
8. The method of claim 5, wherein the regiospecific 
hydroxylation and oxidation are catalyzed by sequential 
enzyme mediated reactions. 
9. The method of any one of claims 6-8, further compris- 30 
ing isolating the nootkatone. 
* * * * * 
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